<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">71154</article-id><article-id pub-id-type="doi">10.7554/eLife.71154</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Skeletal dysplasia-causing TRPV4 mutations suppress the hypertrophic differentiation of human iPSC-derived chondrocytes</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-242470"><name><surname>Dicks</surname><given-names>Amanda R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6036-280X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-142287"><name><surname>Maksaev</surname><given-names>Grigory I</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-242471"><name><surname>Harissa</surname><given-names>Zainab</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-242472"><name><surname>Savadipour</surname><given-names>Alireza</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-148418"><name><surname>Tang</surname><given-names>Ruhang</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-242477"><name><surname>Steward</surname><given-names>Nancy</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-242473"><name><surname>Liedtke</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-22774"><name><surname>Nichols</surname><given-names>Colin G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4929-2134</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-242474"><name><surname>Wu</surname><given-names>Chia-Lung</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9598-7036</contrib-id><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="fn1">†</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-147279"><name><surname>Guilak</surname><given-names>Farshid</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7380-0330</contrib-id><email>guilak@wustl.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="fn1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yc7t268</institution-id><institution>Department of Biomedical Engineering, Washington University in St. Louis</institution></institution-wrap><addr-line><named-content content-type="city">St Louis</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yc7t268</institution-id><institution>Department of Orthopedic Surgery, Washington University School of Medicine, St. Louis</institution></institution-wrap><addr-line><named-content content-type="city">St Louis</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/049mpkx27</institution-id><institution>Shriners Hospitals for Children - St. Louis</institution></institution-wrap><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yc7t268</institution-id><institution>Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis</institution></institution-wrap><addr-line><named-content content-type="city">St Louis</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yc7t268</institution-id><institution>Department of Mechanical Engineering and Material Science, Washington University in St. Louis</institution></institution-wrap><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00py81415</institution-id><institution>Department of Neurology, Duke University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0190ak572</institution-id><institution>Department of Molecular Pathobiology - NYU College of Dentistry</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/022kthw22</institution-id><institution>Department of Orthopaedics and Rehabilitation, Center for Musculoskeletal Research, University of Rochester</institution></institution-wrap><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Chen</surname><given-names>Di</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/034t30j35</institution-id><institution>Chinese Academy of Sciences</institution></institution-wrap><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="other" id="fn1"><label>†</label><p>co-senior author</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>22</day><month>02</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e71154</elocation-id><history><date date-type="received" iso-8601-date="2021-06-10"><day>10</day><month>06</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2023-02-03"><day>03</day><month>02</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-06-15"><day>15</day><month>06</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.06.15.448562"/></event></pub-history><permissions><copyright-statement>© 2023, Dicks et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Dicks et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-71154-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-71154-figures-v2.pdf"/><abstract><p>Mutations in the TRPV4 ion channel can lead to a range of skeletal dysplasias. However, the mechanisms by which TRPV4 mutations lead to distinct disease severity remain unknown. Here, we use CRISPR-Cas9-edited human-induced pluripotent stem cells (hiPSCs) harboring either the mild V620I or lethal T89I mutations to elucidate the differential effects on channel function and chondrogenic differentiation. We found that hiPSC-derived chondrocytes with the V620I mutation exhibited increased basal currents through TRPV4. However, both mutations showed more rapid calcium signaling with a reduced overall magnitude in response to TRPV4 agonist GSK1016790A compared to wildtype (WT). There were no differences in overall cartilaginous matrix production, but the V620I mutation resulted in reduced mechanical properties of cartilage matrix later in chondrogenesis. mRNA sequencing revealed that both mutations up-regulated several anterior <italic>HOX</italic> genes and down-regulated antioxidant genes <italic>CAT</italic> and <italic>GSTA1</italic> throughout chondrogenesis. BMP4 treatment up-regulated several essential hypertrophic genes in WT chondrocytes; however, this hypertrophic maturation response was inhibited in mutant chondrocytes. These results indicate that the TRPV4 mutations alter BMP signaling in chondrocytes and prevent proper chondrocyte hypertrophy, as a potential mechanism for dysfunctional skeletal development. Our findings provide potential therapeutic targets for developing treatments for TRPV4-mediated skeletal dysplasias.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cartilage</kwd><kwd>chondrocyte</kwd><kwd>dysplasia</kwd><kwd>pluripotent stem cell</kwd><kwd>iPSC</kwd><kwd>TRPV4</kwd><kwd>bone</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AG15768</award-id><principal-award-recipient><name><surname>Guilak</surname><given-names>Farshid</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AG46927</award-id><principal-award-recipient><name><surname>Guilak</surname><given-names>Farshid</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>ar072999</award-id><principal-award-recipient><name><surname>Guilak</surname><given-names>Farshid</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AR075899</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Chia-Lung</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Chondrocytes derived from induced pluripotent stem cells with the dysplasia-causing TRPV4 mutations, V620I and T89I mutation, were resistant to BMP4-induced hypertrophy, suggesting a mechanism underlying the effects of TRPV4 dysfunction on the severity of skeletal dysplasia.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Skeletal dysplasias comprise a heterogeneous group of over 450 bone and cartilage diseases with an overall birth incidence of 1 in 5000 (<xref ref-type="bibr" rid="bib45">Krakow and Rimoin, 2010</xref>; <xref ref-type="bibr" rid="bib68">Nemec et al., 2012</xref>; <xref ref-type="bibr" rid="bib69">Ngo et al., 2018</xref>; <xref ref-type="bibr" rid="bib76">Orioli et al., 1986</xref>; <xref ref-type="bibr" rid="bib93">Superti-Furga and Unger, 2007</xref>). Mutations in transient receptor potential vanilloid 4 (TRPV4), a non-selective cation channel, can lead to varying degrees of skeletal dysplasia, including moderate autosomal-dominant brachyolmia and severe metatropic dysplasia (<xref ref-type="bibr" rid="bib5">Andreucci et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Kang, 2012</xref>). For example, a V620I substitution (exon 12, G858A) in TRPV4 is responsible for moderate brachyolmia, which exhibits short stature, scoliosis, and delayed development of deformed bones (<xref ref-type="bibr" rid="bib40">Kang et al., 2012</xref>; <xref ref-type="bibr" rid="bib86">Rock et al., 2008</xref>; <xref ref-type="bibr" rid="bib39">Kang, 2012</xref>). These features, albeit more severe, are also present in metatropic dysplasia. Metatropic dysplasia can be caused by a TRPV4 T89I substitution (exon 2, C366T) and leads to joint contractures, disproportionate measurements, and, in severe cases, neonatal death due to small chest size and cardiopulmonary compromise (<xref ref-type="bibr" rid="bib8">Camacho et al., 2010</xref>; <xref ref-type="bibr" rid="bib40">Kang et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">Kang, 2012</xref>). Both V620I and T89I TRPV4 mutations are considered gain-of-function variants (<xref ref-type="bibr" rid="bib47">Leddy et al., 2014b</xref>; <xref ref-type="bibr" rid="bib55">Loukin et al., 2011</xref>). Given the essential role of TRPV4 during chondrogenesis (<xref ref-type="bibr" rid="bib67">Muramatsu et al., 2007</xref>; <xref ref-type="bibr" rid="bib103">Willard et al., 2021</xref>) and cartilage homeostasis (<xref ref-type="bibr" rid="bib74">O’Conor et al., 2014</xref>), it is hypothesized that TRPV4 mutations may affect endochondral ossification during skeletal development.</p><p>Endochondral ossification is a process by which bone tissue is created from a cartilage template (<xref ref-type="bibr" rid="bib7">Breeland et al., 2021</xref>; <xref ref-type="bibr" rid="bib8">Camacho et al., 2010</xref>; <xref ref-type="bibr" rid="bib45">Krakow and Rimoin, 2010</xref>; <xref ref-type="bibr" rid="bib85">Rimoin et al., 2007</xref>). During this process, chondrocytes transition from maintaining the homeostasis of cartilage, regulated by transcription factor SRY-box containing gene 9 (<italic>SOX9</italic>) (<xref ref-type="bibr" rid="bib7">Breeland et al., 2021</xref>; <xref ref-type="bibr" rid="bib72">Nishimura et al., 2012b</xref>; <xref ref-type="bibr" rid="bib82">Prein and Beier, 2019</xref>; <xref ref-type="bibr" rid="bib90">Sophia Fox et al., 2009</xref>), to hypertrophy. Hypertrophy is driven by runt-related transcription factor 2 (<italic>RUNX2</italic>) and bone morphogenic protein (BMP) signaling (<xref ref-type="bibr" rid="bib7">Breeland et al., 2021</xref>; <xref ref-type="bibr" rid="bib72">Nishimura et al., 2012b</xref>; <xref ref-type="bibr" rid="bib82">Prein and Beier, 2019</xref>) and leads to chondrocyte apoptosis or differentiation into osteoblasts to form bone (<xref ref-type="bibr" rid="bib7">Breeland et al., 2021</xref>; <xref ref-type="bibr" rid="bib72">Nishimura et al., 2012b</xref>; <xref ref-type="bibr" rid="bib82">Prein and Beier, 2019</xref>). However, how TRPV4 and its signaling cascades regulate endochondral ossification remains to be determined.</p><p>The activation of TRPV4 increases <italic>SOX9</italic> expression (<xref ref-type="bibr" rid="bib67">Muramatsu et al., 2007</xref>) and prevents chondrocyte hypertrophy and endochondral ossification (<xref ref-type="bibr" rid="bib4">Amano et al., 2009</xref>; <xref ref-type="bibr" rid="bib30">Hattori et al., 2010</xref>; <xref ref-type="bibr" rid="bib58">Lui et al., 2019</xref>; <xref ref-type="bibr" rid="bib71">Nishimura et al., 2012a</xref>; <xref ref-type="bibr" rid="bib72">Nishimura et al., 2012b</xref>). One study found that overexpressing wildtype (WT) <italic>Trpv4</italic> in mouse embryos increased intracellular calcium (Ca<sup>2+</sup>) concentration and delayed bone mineralization (<xref ref-type="bibr" rid="bib100">Weinstein et al., 2014</xref>), a potential link between intracellular Ca<sup>2+</sup>, such as with gain-of-function TRPV4 mutations, and delayed endochondral ossification. Our previous study also observed increased expression of follistatin (<italic>FST</italic>), a potent BMP inhibitor, and delayed hypertrophy in porcine chondrocytes overexpressing human V620I- and T89I-TRPV4 (<xref ref-type="bibr" rid="bib46">Leddy et al., 2014a</xref>; <xref ref-type="bibr" rid="bib47">Leddy et al., 2014b</xref>). While previous studies have greatly increased our knowledge of the influence of TRPV4 mutations on chondrogenesis and hypertrophy, most of them often involved animal models (<xref ref-type="bibr" rid="bib47">Leddy et al., 2014b</xref>; <xref ref-type="bibr" rid="bib100">Weinstein et al., 2014</xref>) or cells (<xref ref-type="bibr" rid="bib8">Camacho et al., 2010</xref>; <xref ref-type="bibr" rid="bib45">Krakow and Rimoin, 2010</xref>; <xref ref-type="bibr" rid="bib47">Leddy et al., 2014b</xref>; <xref ref-type="bibr" rid="bib55">Loukin et al., 2011</xref>; <xref ref-type="bibr" rid="bib86">Rock et al., 2008</xref>) overexpressing mutant TRPV4. Therefore, these approaches may not completely recapitulate the effect of TRPV4 mutations on human chondrogenesis.</p><p>Human-induced pluripotent stem cells (hiPSCs), derived from adult somatic cells (<xref ref-type="bibr" rid="bib95">Takahashi et al., 2007</xref>), offer a system for modeling human disease to study the effect of mutations throughout differentiation (<xref ref-type="bibr" rid="bib1">Adkar et al., 2017</xref>; <xref ref-type="bibr" rid="bib48">Lee et al., 2021</xref>). In fact, two studies have used patient-derived hiPSCs with TRPV4 mutations to study lethal and non-lethal metatropic dysplasia-causing variants I604M (<xref ref-type="bibr" rid="bib87">Saitta et al., 2014</xref>) and L619F (<xref ref-type="bibr" rid="bib73">Nonaka et al., 2019</xref>), respectively. However, patient samples are often challenging to procure due to the rarity of skeletal dysplasias. In this regard, CRISPR-Cas9 technology allows the creation of hiPSC lines harboring various mutations along with isogenic controls (i.e., WT).</p><p>The goal of this study was to elucidate the molecular mechanisms underlying how two TRPV4 gain-of-function mutations lead to strikingly distinct severities of skeletal dysplasias (i.e., moderate brachyolmia vs. lethal metatropic dysplasia). To achieve this goal, we generated CRISPR-Cas9 gene-edited hiPSC lines bearing either the V620I or T89I TRPV4 mutation, and their isogenic WT control, to delineate the effects of TRPV4 mutations on chondrogenesis and hypertrophy using RNA sequencing and transcriptomic analysis. We further examined the effects of the mutations on channel function and matrix production and properties. We hypothesized the V620I and T89I TRPV4 mutations would enhance chondrogenesis with distinct degrees of altered hypertrophy. This study will improve our understanding of the role of TRPV4 in chondrocyte homeostasis and maturation and lay the foundation for treatment and prevention of TRPV4-mediated dysplasias.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Mutant TRPV4 has altered response to chemical agonist GSK101</title><p>We first assessed TRPV4 channel function and alterations in Ca<sup>2+</sup> signaling due to the V620I and T89I mutations in day-28 hiPSC-derived chondrocytes using electrophysiology and fluorescence imaging. Using whole-cell patch clamping, we measured the basal membrane current of the hiPSC-derived chondrocytes from the mutated and WT lines. V620I-TRPV4 had the highest basal currents at both 70 and −70 mV (70/−70 mV pA/pF – WT: 18.52/5.93 vs. V602I: 77.79/55.33 vs. T89I: 40.97/50.13; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). However, when TRPV4 was inhibited with GSK205 (<xref ref-type="bibr" rid="bib41">Kanju et al., 2016</xref>), a TRPV4-specfic chemical antagonist, the three lines had similar, decreased currents (70/−70 mV – WT: 18.72/14.36 pA/pF vs. V620I: 13.55/9.15 pA/pF vs. T89I: 29.27/13.8 pA/pF; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). To capture the specific current through TRPV4, we took the difference of the basal current (no GSK205) and the average TRPV4-inhibited current (with GSK205). TRPV4 inhibition caused a significant change in current in V620I at both 70 and −70 mV (70 mV – V620I: Δ64.28 vs. WT: Δ –0.19, p = 0.0379 and T89I: Δ11.67, p &lt; 0.0001; −70 mV – V620I: Δ46.13 vs. WT: Δ −8.47, p &lt; 0.0001 and T89I: Δ36.33, p = 0.0057; <xref ref-type="fig" rid="fig1">Figure 1B</xref>). Interestingly, T89I-TRPV4 was not significantly different from WT despite also causing a gain-of-function in recombinant channels (<xref ref-type="bibr" rid="bib55">Loukin et al., 2011</xref>). Further, the increase in signaling in V620I only may indicate different mechanisms of action leading to the varying disease caused by the two mutations.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Differences in TRPV4 electrophysiological properties of wildtype (WT) and mutant human-induced pluripotent stem cell (hiPSC)-derived chondrocytes.</title><p>(<bold>A</bold>) Whole-cell currents were higher, on average, in mutant hiPSC-derived chondrocytes than WT at 70 and −70 mV. TRPV4 inhibition with 20 µM GSK205 reduced mutant currents to similar levels as WT. Mean ± standard error of the mean (SEM). <italic>n</italic> = 20–40 cells from 4 differentiations. Kruskal-Wallis test with multiple comparisons comparing cell lines at 70 and -70 mV. No significance. (<bold>B</bold>) The difference between the current (<italic>I</italic>) through TRPV4 without GSK205 from the average current through inhibited channels was significantly higher in V620I. There was no difference between no drugs and GSK205 in WT. Mean ± SEM. <italic>n</italic> = 27–40 from 4 differentiations. Kruskal–Wallis test with multiple comparisons comparing cell lines at 70 and −70 mV. *p &lt; 0.05, **p &lt; 0.01, ****p &lt; 0.001. (<bold>C</bold>) Inside-out excised patches of WT had a higher current in response to 10 nM GSK101 (indicated by *) than mutants. The addition of 10 nM GSK101 + 20 µM GSK205 (indicated by arrow head) decreased the current and continued to block the channel when GSK101 alone was re-introduced (*). Representative plots with average unitary current and current in response to GSK101. Mean ± SEM. <italic>N</italic> = 5, 9, and 8 for WT, V620I, and T89I, respectively, from 2 differentiations. (<bold>D</bold>) Mutant TRPV4 decreased the channels’ sensitivity to activation with GSK101 (indicated by arrow) as shown with confocal imaging of ratiometric fluorescence indicating Ca<sup>2+</sup> signaling. GSK205 attenuated GSK101-mediated signaling. Mean ± 95% CI. <italic>n</italic> = 3 experiments with a total of 158–819 cells per line. (<bold>E</bold>) Quantification of the area under the curve of (<bold>D</bold>). Mean ± SEM. <italic>n</italic> = 158–819 cells from 3 experiments. Ordinary two-way analysis of variance (ANOVA) with Tukey’s post hoc test. Interaction, cell line, and treatment p &lt; 0.0001. Different letters are significantly different, p &lt; 0.05, from each other. (<bold>F</bold>) Time of initial response of each responding cell (≥25% of frames for that cell are responding) measured from the addition of stimulus. Mutant TRPV4 responded faster to GSK101, but the response was significantly slowed by GSK205. Responding frames were considered to have a fluorescence greater than the mean plus three times the standard deviation. Mean ± SEM. <italic>n</italic> = 21–360 responding cells from 3 experiments. Ordinary two-way ANOVA with Tukey’s post hoc test. Interaction, cell line, and treatment p &lt; 0.0001.Different letters are significantly different, p &lt; 0.05, from each other.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-71154-fig1-v2.tif"/></fig><p>Next, we activated WT and mutant TRPV4 with chemical agonist GSK1016790A (GSK101) (<xref ref-type="bibr" rid="bib38">Jin et al., 2011</xref>) and found that the mutations decreased the cellular response to the agonist, resulting in reduced Ca<sup>2+</sup> signaling. These results were supported using two methods: inside-out excised patches and confocal imaging of Ca<sup>2+</sup> signaling (<xref ref-type="fig" rid="fig1">Figure 1C, D</xref>). The representative traces of inside-out patches showed increased current through the patch with the addition of GSK101 and the attenuation by GSK205 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). GSK205 continued to block the channel and prevented another increase in current despite the addition of GSK101. Though the unitary currents were indistinguishable (8 pA at −30 mV) among WT and mutants, in excised inside-out patches, WT typically produced higher GSK101-induced currents than the mutants (WT: 290 pA vs. V620I: 87.1 pA and T89I: 62.3 pA at −30 mV), potentially indicative of more channels per patch (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). In the confocal imaging experiments, a ratiometric fluorescence indicated Ca<sup>2+</sup> signaling of the hiPSC-derived chondrocytes in response to either 10 nM GSK101 or a cocktail of 10 nM GSK101 and 20 µM GSK205. WT cells had significantly higher fluorescence, and therefore Ca<sup>2+</sup> signaling, in response to GSK101 according to the plots and their area under the curve (WT: 1470 vs. V620I: 1114 and T89I: 1044; p &lt; 0.0001; <xref ref-type="fig" rid="fig1">Figure 1D, E</xref>). The presence of GSK205 attenuated this response for all three lines, confirming the Ca<sup>2+</sup> influx was due to the TRPV4 ion channel (WT: 366 vs. V620I: 460 vs. T89I: 358). We also evaluated the response time of the cells to GSK101 and GSK101 + GSK205. We considered a cell to be responding if more than a quarter of its frames, after stimuli, had a fluorescence higher than the mean baseline plus 3 times the standard deviation. The mutants responded faster to GSK101 than the WT (WT: 46.2 s vs. V620I: 12 s, p = 0.0048 and T89I: 10.8 s, p = 0.0097; <xref ref-type="fig" rid="fig1">Figure 1F</xref>). Interestingly, the addition of GSK205 did not significantly slow the response of WT, but it did slow the response of the mutants, with the severe mutation slower than the moderate (WT: 35.4 s vs. V620I: 234 s and T89: 366 s; p &lt; 0.0001; <xref ref-type="fig" rid="fig1">Figure 1F</xref>). These data highlight that the mutations alter the activation kinetics of TRPV4, which could play a role in the disease phenotype.</p></sec><sec id="s2-2"><title>Chondrogenic differentiation of WT and mutant hiPSC lines</title><p>To investigate if the hiPSCs with dysplasia-causing mutations exhibit altered chondrogenesis, we differentiated CRISPR-Cas9-edited hiPSCs with mutant <italic>TRPV4</italic> alongside an isogenic WT using our previously published protocol (<xref ref-type="bibr" rid="bib2">Adkar et al., 2019</xref>; <xref ref-type="bibr" rid="bib106">Wu et al., 2021</xref>). After 12 days of monolayer mesodermal differentiation, the cells underwent 42 days of chondrogenic differentiation, and pellets were collected at days 7, 14, 28, and 42. Since we had previously shown that 28 days is sufficient for hiPSC chondrogenesis, day 28 was our primary time point while days 7 and 14 identified changes during differentiation. We included day 42 data in the supplement to investigate any potential changes in transcriptomic profiles and cartilaginous matrix production in chondrocyte maturation. At day 28, the three lines had similar chondrogenic matrix as shown with Safranin-O staining for sulfated glycosaminoglycans (sGAGs) and collagen type 2 alpha chain 1 (COL2A1) labeling with immunohistochemistry (IHC; <xref ref-type="fig" rid="fig2">Figure 2A, B</xref>). All three lines had little to no labeling of fibrocartilage marker COL1A1 and hypertrophic cartilage marker COL10A1 with IHC (<xref ref-type="fig" rid="fig2">Figure 2C, D</xref>). To quantitatively confirm the matrix production throughout chondrogenesis, we performed biochemical assays to measure sGAG production and normalized it to double-stranded DNA content. As expected, differences in matrix production were significant between time points (p &lt; 0.0001; <xref ref-type="fig" rid="fig2">Figure 2E</xref>). The sGAG/DNA ratio increased in WT by 8-fold and in V620I and T89I by 5- to 5.5-fold from day 14 to 28 (p &lt; 0.0001; <xref ref-type="fig" rid="fig2">Figure 2E</xref>). V620I pellets also increased in matrix content by 150% from day 28 to 42 (p = 0.0163; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 2–1A</xref>) with all three lines reaching an sGAG/DNA ratio of approximately 30. However, there were no differences in sGAG/DNA ratios among the three cell lines at any time point (cell line: p = 0.1206; interaction: p = 0.7426; <xref ref-type="fig" rid="fig2">Figure 2E</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Mutant TRPV4 had little effect on chondrogenic matrix production.</title><p>(<bold>A</bold>) Wildtype (WT), V620I, and T89I day-28 pellets exhibit similar matrix production shown by staining for sulfated glycosaminoglycans (sGAGs) with Safranin-O and hematoxylin and labeling with immunohistochemistry (IHC) for (<bold>B</bold>) COL2A1 (<bold>C</bold>), COL1A1 (<bold>D</bold>), and COL10A1. Scale bar = 500 µm. Representative images from 3 to 4 differentiations. (<bold>E</bold>) The sGAG/DNA ratio increased in all three lines from day 14 to 28 of chondrogenesis. There were no differences between lines at each time point. Mean ± standard error of the mean (SEM). <italic>n</italic> = 11–16 from 3 to 4 independent differentiation experiments. ****p &lt; 0.0001 Statistical significance determined by an ordinary two-way analysis of variance (ANOVA) with Tukey’s post hoc test. (<bold>F</bold>) There were no differences in the elastic modulus of the matrix at day 28. Mean ± SEM. <italic>n</italic> = 11–14 from 3 experiments. Statistical significance determined by an ordinary two-way ANOVA with Tukey’s post hoc test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-71154-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Minor differences in V620I matrix were observed at day 42 of chondrogenesis.</title><p>(<bold>A</bold>) The sulfated glycosaminoglycan (sGAG)/DNA ratio increased in all three lines from day 14 to 28 of chondrogenesis. V620I also had an increase in the sGAG/DNA ratio from day 28 to 42. There were no differences between lines at each time point. Mean ± standard error of the mean (SEM). <italic>n</italic> = 11–16 from 3 to 4 differentiation experiments. ****p &lt; 0.0001, <sup>#</sup>p &lt; 0.05 to day-28 V620I. Statistical significance determined by an ordinary two-way analysis of variance (ANOVA) with Tukey’s post hoc test. (<bold>B</bold>) There were no differences in the elastic modulus of the matrix at day 28. Day-42 V620I had a significantly lower elastic modulus than wildtype (WT) and T89I. Mean ± SEM. <italic>n</italic> = 11–14 from 3 experiments. *p &lt; 0.05, ***p &lt; 0.001 Statistical significance determined by an ordinary two-way ANOVA with Tukey’s post hoc test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-71154-fig2-figsupp1-v2.tif"/></fig></fig-group><p>Atomic force microscopy (AFM) was then used to measure the mechanical properties of the hiPSC-derived cartilaginous matrix deposited by the WT and two TRPV4-mutated cell lines. The elastic modulus ranged from 14 to 20 kPa, consistent with mouse iPSC-derived cartilage (<xref ref-type="bibr" rid="bib22">Diekman et al., 2012</xref>). At day 28, the three lines had similar properties (WT: 14.4 kPa vs. V620I: 15.9 kPa vs. T89I: 14.8 kPa; <xref ref-type="fig" rid="fig2">Figure 2F</xref>); however, at day 42, V620I had a significantly decreased elastic modulus (V620I: 10.32 kPa vs. WT: 20.0 kPa, p = 0.0004 and T89I: 17.5 kPa, p = 0.0328; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 2–1B</xref>). These experiments indicated that all three lines properly differentiated into chondrocytes and had similar cartilaginous matrix production at day 28. With 14 more days of chondrogenic culture, minor differences in matrix accumulation were observed with the moderate V620I line.</p></sec><sec id="s2-3"><title>TRPV4 mutations altered chondrogenic gene expression in hiPSC-derived chondrocytes</title><p>Reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis throughout differentiation shows that mutants had higher <italic>ACAN</italic> expression compared to WT at day 28 (day-28 fold changes; WT: 2314 vs. V620I: 6418, p = 0.1092 and T89I: 5870, p = 0.0316; <xref ref-type="fig" rid="fig3">Figure 3A</xref>); however, expression decreased at day 42 in T89I (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). <italic>COL2A1</italic> expression was similar among the three lines at day 28 (day-28 fold changes; WT: 6492 vs. V620I: 6524, p &gt; 0.9999 and T89I: 8131, p = 0.3304; <xref ref-type="fig" rid="fig3">Figure 3B</xref>) but significantly lower in T89I at day 42 (day-42 fold changes; T89I: 2798 vs. WT: 9209, p = 0.0144 and V620I: 7177, p = 0.0007; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Throughout chondrogenesis, V620I significantly increased expression of chondrogenic transcription factor <italic>SOX9</italic> (day-28 fold changes; V620I: 178.9 vs. WT: 49.16, p = 0.0011 and T89I: 55.37, p = 0.0117; <xref ref-type="fig" rid="fig3">Figure 3C</xref>) and <italic>TRPV4</italic> (day-28 fold changes; V620I: 112.1 vs. WT: 42.14, p &lt; 0.0001 and T89I: 45.82, p = 0.0002; <xref ref-type="fig" rid="fig3">Figure 3D</xref>). On the other hand, T89I significantly increased expression of pro-inflammatory, calcium-binding protein <italic>S100B</italic> (<xref ref-type="bibr" rid="bib107">Yammani, 2012</xref>) throughout chondrogenesis (day-28 fold changes; T89I: 2552 vs. WT: 415.8, p &lt; 0.0001 and V620I: 633.6, p = 0.0019; <xref ref-type="fig" rid="fig3">Figure 3E</xref>). T89I also had significantly higher expression of fibrocartilage marker <italic>COL1A1</italic> at days 7, 14, and 28 than the other two lines (day-28 fold changes; T89I: 80.33 vs. WT: 13.15, p &lt; 0.0001 and V620I: 23.61, p = 0.0043; <xref ref-type="fig" rid="fig3">Figure 3F</xref>), and both mutations had increased expression at day 42 compared to WT (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>). In contrast, hypertrophic marker <italic>COL10A1</italic> was significantly higher in the WT line than the mutants at days 28 and 42 (day-28 fold changes; WT: 310.4 vs. V620I: 30.26, p = 0.0338 and T89I: 52.92, p = 0.0033; <xref ref-type="fig" rid="fig3">Figure 3G</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G</xref>). Surprisingly, there was no significant increase in follistatin (<italic>FST</italic>) expression in mutants at later time points (day-28 fold changes; WT: 0.7042 vs. V620I: 0.4025, p = 0.6228 and T89I: 0.4242, p &gt; 0.9999; <xref ref-type="fig" rid="fig3">Figure 3H</xref>) despite previous findings (<xref ref-type="bibr" rid="bib47">Leddy et al., 2014b</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>V620I and T89I exhibited differing effects on gene expression during chondrogenic differentiation.</title><p>(<bold>A</bold>) V620I and T89I had increased <italic>ACAN</italic> gene expression at day 28 compared to wildtype (WT). (<bold>B</bold>) The three lines had similar <italic>COL2A1</italic> expression throughout differentiation. V620I increased expression of (<bold>C</bold>) <italic>SOX9</italic> and (<bold>D</bold>) <italic>TRPV4</italic> throughout chondrogenesis. T89I increased expression of (<bold>E</bold>) <italic>S100B</italic> and (<bold>F</bold>) <italic>COL1A1</italic> throughout chondrogenesis. (<bold>G</bold>) Both mutations decreased <italic>COL10A1</italic> gene expression at day 28 compared to WT. (<bold>H</bold>) There were no differences in <italic>FST</italic> expression at day 28. Mean ± standard error of the mean (SEM). <italic>n</italic> = 10–12 from 3 independent differentiation experiments. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001 Significance determined by one-way analysis of variance (ANOVA) with Tukey’s post hoc test for each time point.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-71154-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>V620I and T89I had differing effects on gene expression during chondrogenic differentiation.</title><p>(<bold>A</bold>) T89I and V620I had increased <italic>ACAN</italic> gene expression at days 28 and 42, respectively, compared to wildtype (WT). (<bold>B</bold>) Day-42 T89I chondrocytes had decreased expression of <italic>COL2A1</italic>. V620I increased expression of <italic>SOX9</italic> (<bold>C</bold>) and <italic>TRPV4</italic> (<bold>D</bold>) throughout chondrogenesis. T89I increased expression of <italic>S100B</italic> (<bold>E</bold>) and <italic>COL1A1</italic> (<bold>F</bold>) throughout chondrogenesis. (<bold>G</bold>) Both mutations decreased <italic>COL10A1</italic> gene expression at days 28 and 42, compared to WT. (<bold>H</bold>) There were no differences in <italic>FST</italic> expression at later time points days 28 and 42. Mean ± standard error of the mean (SEM). <italic>n</italic> = 10–12 from 3 differentiations. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001. Significance determined by one-way analysis of variance (ANOVA) with Tukey’s post hoc test for each time point.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-71154-fig3-figsupp1-v2.tif"/></fig></fig-group><p>To obtain comprehensive transcriptomic profiles of WT and TRPV4-mutated cell lines, we performed bulk RNA sequencing of day-28 chondrogenic pellets. We compared V620I and T89I gene expression to WT and plotted the log<sub>2</sub> fold change in heatmaps (<xref ref-type="fig" rid="fig4">Figure 4A, B</xref>). While many chondrogenic and hypertrophic genes had similar levels of expression between the lines, the mutants had increased expression of cartilage oligomeric matrix protein (<italic>COMP</italic>), collagen type VI alpha chains 1 and 3 (<italic>COL6A1</italic>, <italic>COL6A3</italic>), growth differentiation factor 5 (<italic>GDF5</italic>), high-temperature requirement A serine peptidase 1 (<italic>HTRA1</italic>), and secreted protein acidic and cysteine rich (<italic>SPARC</italic>) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Additionally, the mutations up-regulated expression levels of bone morphogenic protein 6 (<italic>BMP6</italic>), transforming growth factor 3 (<italic>TGFB3</italic>), nuclear factor of activated T-Cells C2 (<italic>NFATC2</italic>), Twist family BHLH transcription factor 1 (<italic>TWIST1</italic>), ADAM metallopeptidase with thrombospondin type 1 motif 4 (<italic>ADAMTS4</italic>), and <italic>WNT3A</italic> (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). In contrast, the mutants had decreased expression of hypertrophic markers <italic>COL10A1</italic>, secreted phosphoprotein 1 (<italic>SPP1</italic>), and alkaline phosphatase, biomineralization associated (<italic>ALPL</italic>) (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The mutations also down-regulated osteoblastogenesis transcription factors <italic>SOX2</italic> and <italic>SOX11</italic> and previously identified genes governing off-target differentiation during hiPSC chondrogenesis including nestin (<italic>NES</italic>), orthodenticle homeobox 2 (<italic>OTX2</italic>), <italic>WNT7A</italic>, and <italic>WNT7B</italic> (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Overall, these results indicate the mutant chondrocytes express higher levels of chondrogenic markers and lower levels of genes associated with hypertrophy compared to WT.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Dynamic changes in transcriptomic profiles of V620I and T89I mutants during chondrogenesis.</title><p>Heatmaps comparing the log<sub>2</sub> fold change of common chondrogenic and hypertrophic genes (<bold>A</bold>) and growth factor and signaling genes (<bold>B</bold>) in day-28 V620I and T89I chondrocytes compared to wildtype (WT). (<bold>C</bold>) Clustering of the samples using Euclidean distances reveals that V620I and T89I human-induced pluripotent stem cell (hiPSC)-derived chondrocytes are more similar to each other than WT. (<bold>D</bold>) The number of up- and down-regulated differentially expressed genes (DEGs) in V620I and T89I day-28 chondrocytes compared to WT. (<bold>E–G</bold>) Analysis of the down-regulated genes compared to WT. (<bold>E</bold>) A Venn diagram reveals the number of similar and different down-regulated DEGs between V620I and T89I, where most genes are shared. (<bold>F</bold>) A heatmap showing the log<sub>2</sub> fold change, compared to WT, of the top 25 down-regulated genes for each line. (<bold>G</bold>) The top 3 Gene Ontology (GO) terms (biological process) associated with the DEGs unique to V620I, shared between V620I and T89I, and unique to T89I. Symbol color represents the cell line, and size represents the −log<sub>10</sub>(p<sub>adj</sub>).(<bold>H–J</bold>) Analysis of the up-regulated genes compared to WT. (<bold>H</bold>) A Venn diagram reveals the number of similar and different up-regulated DEGs between V620I and T89I, where most genes are shared. (<bold>I</bold>) A heatmap showing the log<sub>2</sub> fold change, compared to WT, of the top 25 up-regulated genes for each line. (<bold>J</bold>) The top 3 GO terms (biological process) associated with the DEGs unique to V620I, shared between V620I and T89I, and unique to T89I. Symbol color represents the cell line, and size represents the −log<sub>10</sub>(p<sub>adj</sub>). (<bold>K</bold>) Clustering of the day-28 and -56 samples using Euclidean distances reveals that the WT chondrocytes, at both days 28 and 56, cluster together while mutants cluster by time point. (<bold>L</bold>) The number of up- and down-regulated DEGs for V620I and T89I compared to WT at days 28 and 56. (<bold>M</bold>) A Venn diagram reveals the number of similar and different up-regulated DEGs between V620I and T89I, with T89I becoming more unique at day 56. <italic>n</italic> = 3–4 samples.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-71154-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Distinction between V620I and T89I.</title><p>Moderate V620I and severe T89I mutations have distinct gene expression after 28 and 56 days of chondrogenic differentiation with TGFβ3. (<bold>A</bold>) A heatmap representing the log<sub>2</sub> fold change, compared to wildtype (WT), of the top 15 most up- and down-regulated genes unique to V620I and T89I at day 28. (<bold>B</bold>) The expression of protein kinase C alpha (<italic>PRKCA</italic>) at day 28 for WT, V620I, and T89I represented by normalized counts. *p<sub>adj</sub> ≤ 0.1 and log<sub>2</sub>(fold change) ≥1 (i.e., differentially expressed). (<bold>C</bold>) A heatmap representing the log<sub>2</sub> fold change, compared to WT, of the top 15 most up- and down-regulated genes unique to V620I and T89I at day 56. (<bold>D</bold>) The expression of catenin beta 1 (<italic>CTNNB1</italic>) at day 56 for WT, V620I, and T89I represented by normalized counts. *p<sub>adj</sub> ≤ 0.1 and log<sub>2</sub>(fold change) ≥1 (i.e., differentially expressed).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-71154-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Top differentially expressed genes (DEGs) of V620I and T89I chondrocytes compared to wildtype (WT) remain from day 28 to 56.</title><p>(<bold>A</bold>) The top 25 up-regulated genes, and their log<sub>2</sub> fold change, for day-56 TGFβ3-treated V620I and T89I chondrocytes compared WT. (<bold>B</bold>) The top 25 down-regulated genes, and their log<sub>2</sub> fold change, for day-56 TGFβ3-treated V620I and T89I chondrocytes compared WT.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-71154-fig4-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>V620I and T89I mutants demonstrate similar gene expression profiles early in differentiation</title><p>First, to evaluate the similarities and differences in transcriptomic profiles between the hiPSC-derived chondrocytes with and without the TRPV4 mutations, we computed the Euclidean distance between day-28 samples of each cell line. The WT samples clustered away from the mutants, and the V620I samples were the most variable. (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). In terms of total differentially expressed genes (DEGs) compared to WT, V620I had 8% fewer DEGs than T89I (2459 vs. 2671; <xref ref-type="fig" rid="fig4">Figure 4D</xref>). Mutants had only about half of the number of up-regulated genes compared to down-regulated genes (V620I: 884 vs. 1575, T89I: 978 vs. 1693; <xref ref-type="fig" rid="fig4">Figure 4D</xref>). The majority of the down-regulated DEGs were shared between the two mutants when compared to WT, comprising 76% and 71% of V620I’s and T89I’s total down-regulated DEGs, respectively (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). We plotted the top 25 most down-regulated DEGs for each line in a heatmap. These included antioxidant catalase (<italic>CAT</italic>), anti-inflammatory nucleotide-binding and leucine-rich repeat receptor family pyrin domain containing 2 (<italic>NLRP2</italic>)<italic>,</italic> and Kruppel-like factor 8 (<italic>KLF8</italic>) (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Interestingly, many of the down-regulated DEGs, both unique and shared between V620I and T89I, were associated with Gene Ontology (GO) terms related to nervous system development, including many potassium channel genes (i.e., <italic>KCN</italic> family; <xref ref-type="fig" rid="fig4">Figure 4G</xref>). This finding is potentially indicative of changes in ion channel signaling beyond TPRV4 with the mutations.</p><p>In contrast, 686 up-regulated DEGs were shared by both mutants, while 22% of V620I’s and 30% of T89I’s up-regulated DEGs were unique to each mutation (198 vs. 292; <xref ref-type="fig" rid="fig4">Figure 4H</xref>). A heatmap of the top 25 up-regulated DEGs showed that several homeobox (HOX) genes were highly expressed in chondrocytes with the TRPV4 mutations (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). These included <italic>HOXA2</italic> to <italic>HOXA7</italic>, <italic>HOXA-AS2</italic>, <italic>HOXB2</italic> to <italic>HOXB4</italic>, and <italic>HOXB-AS1</italic>, which are associated with morphogenesis and anterior patterning (<xref ref-type="bibr" rid="bib88">Seifert et al., 2015</xref>). Furthermore, the shared, up-regulated DEGs between two mutants are associated with extracellular matrix production and organization and growth factor binding in GO term analysis, while V620I genes were associated with type I interferon (<xref ref-type="fig" rid="fig4">Figure 4J</xref>). These data highlighted an early morphogenic genetic profile in hiPSC-derived chondrocytes with the V620I and T89I mutations.</p><p>Additionally, while mutated chondrocytes were more similar to each other compared to WT, we identified a set of genes that may regulate the different disease phenotypes of moderate brachyolmia and severe metatropic dysplasia caused by the V620I and T89I mutation, respectively. For example, the top 15 up- and down-regulated genes unique to either V620I or T89I were plotted in a heatmap (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Interferon-induced protein with tetratricopeptide repeats 3 (<italic>IFIT3</italic>), interferon-induced GTP-binding protein Mx1 (<italic>MX1</italic>), and p53 up-regulated regulator of p53 levels (<italic>PURPL</italic>) were all up-regulated in V620I, but not T89I, consistent with the associated pathways regarding interferon signaling (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref> and <xref ref-type="fig" rid="fig4">Figure 4J</xref>). Interestingly interferonopathies with enhanced type 1 signaling may lead to intracranial calcification and skeletal development problems (<xref ref-type="bibr" rid="bib108">Yu and Song, 2020</xref>). We also observed that protein kinase C alpha (PKC; <italic>PRKCA</italic>), which plays a role in the phosphorylation of TRPV4, was up-regulated in V620I compared to WT (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). V620I also uniquely had many down-regulated genes related to DNA- and RNA-binding such as zinc finger proteins (<italic>ZNF736</italic>, <italic>ZNF717</italic>, and <italic>ZNF594</italic>) and ribosomal protein S4 y-linked 1 (<italic>RPS4Y1</italic>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). T89I had much higher expression of micro-RNA <italic>MIR1245A</italic>, compared to both WT and V620I, which has been shown to increase proliferation in colon cancer (<xref ref-type="bibr" rid="bib78">Pan et al., 2019</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Developmental protein dickkopf WNT signaling pathway inhibitor 2 (<italic>DKK2</italic>) and carbonic anhydrase 2 (<italic>CA2</italic>), which is essential for bone resorption, were also uniquely up-regulated in T89I at day 28 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). In contrast, T89I had reduced expression of bone matrix structural protein bone sialoprotein II (<italic>IBSP</italic>) and limb development transcription factor <italic>SP9</italic> (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). These mutant-specific DEGs highlight that the severe T89I mutation began to have a unique skeletal development transcriptome as early as day 28.</p></sec><sec id="s2-5"><title>The severe T89I mutation inhibits chondrocyte hypertrophy more than moderate V620I mutation</title><p>Following an additional 4 weeks of chondrogenic culture, we performed RNA sequencing to investigate how the differences between the WT and the two mutants change with further differentiation. Using Euclidean distances, we compared the WT, V620I, and T89I hiPSC-derived chondrocytes at both days 28 and 56 (<xref ref-type="fig" rid="fig4">Figure 4K</xref>). WT clustered together at both days 28 and 56; however, the mutants clustered by time point. Again, there were more down-regulated genes than up-regulated at day 56 (<xref ref-type="fig" rid="fig4">Figure 4L</xref>). The lethal, metatropic-dysplasia-causing T89I mutation had the most DEGs, and the number increased from day 28 to 56. In contrast, the moderate, brachyolmia-causing V620I mutation DEGs decreased at day 56. 74% of V620I up-regulated DEGs, but only 24% of T89I DEGs, were shared between the two lines (424 total genes; <xref ref-type="fig" rid="fig4">Figure 4M</xref>). These intersecting, up-regulated genes were associated with the biological processes of skeletal development, morphogenesis, and patterning due to the up-regulation of many <italic>HOX</italic> genes (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). Most of the top up- and down-regulated genes were consistent between days 28 and 56 (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A–B</xref>), including both anterior and posterior <italic>HOX</italic> genes (i.e., <italic>HOXA1</italic> to <italic>HOXA7</italic>, <italic>HOXB2</italic> to <italic>HOXB4</italic>, <italic>HOXB6</italic> to <italic>HOXB8</italic>, <italic>HOXC4</italic>, <italic>HOXD8</italic>, <italic>HOXA-AS2-3</italic>, and <italic>HOXB-AS1-2</italic>) (<xref ref-type="bibr" rid="bib88">Seifert et al., 2015</xref>). Although V620I and T89I TRPV4 mutants continued to share the up-regulated <italic>HOX</italic> genes, which may be responsible for dysfunctional chondrogenic hypertrophy compared to WT cells, our results also indicate that these two mutated lines started to demonstrate further divergent transcriptomic profiles in later chondrogenesis. We observed more up- and down-regulated DEGs in T89I vs. WT compared to V620I vs. WT. Insulin growth factor-like family member 3 (<italic>IGFFL3</italic>) and matrix extracellular phosphoglycoprotein (<italic>MEPE</italic>) were significantly up-regulated in T89I; however, they were slightly down-regulated in V620I, compared to WT (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). T89I also up-regulated calcium-binding proteins annexin A8 (<italic>ANXA8</italic>) and <italic>S100A3</italic> (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). Consistent with its regulation of many Wnt-related genes, T89I up-regulated beta catenin (<italic>CTNNB1</italic>) compared to WT at day 56 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). Both T89I and V620I uniquely down-regulated DNA- and RNA-binding genes, such as various zinc finger proteins, with many of same up- and down-regulated genes in V620I at day 56 as 28 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). Moderate V620I’s difference from WT remained, while T89I continued to diverge with further differentiation.</p></sec><sec id="s2-6"><title>TRPV4 mutations exhibit dysregulated BMP4-induced chondrocyte hypertrophy</title><p>To evaluate how TRPV4 mutations may affect hypertrophy, BMP4 was added to the chondrogenic medium with and without TGFβ3 to stimulate hypertrophic differentiation starting at day 28 of chondrogenic pellet culture (<xref ref-type="bibr" rid="bib15">Craft et al., 2015</xref>). At day 56, Safranin-O staining indicated the BMP4-treated WT had developed a more hypertrophic phenotype compared to TGFβ3- and TGFβ3 + BMP4-treated pellets with enlarged chondrocytes (cell diameter; WT-BMP4: 27.6 µm vs. WT-TGFβ3: 11.8 µm, V620I-BMP4: 12.5 µm, and T89I-BMP4: 11.3 µm; p &lt; 0.0001; <xref ref-type="fig" rid="fig5">Figure 5A, B</xref>). This phenotype was not present in any of the groups from the V620I and T89I lines. Western blot and RNA sequencing further confirmed BMP4-induced hypertrophy was more prominent in the WT line. There was an increase in gene expression and protein production of hypertrophic cartilage markers COL10A1, ALPL, IHH, RUNX2 isoform 9 (RUNX2-9) in all three lines with BMP4 treatment; however, there was a stronger effect in WT (<xref ref-type="fig" rid="fig5">Figure 5C</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Additionally, only BMP4-treated WT had an increase in RUNX2 (<xref ref-type="fig" rid="fig5">Figure 5C</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). These data also highlight the stratification between the moderate V620I and severe T89I mutations as BMP4-treated T89I had lower expression and production of COL10A1, ALPL, and IHH compared to BMP4-treated V620I (<xref ref-type="fig" rid="fig5">Figure 5C</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Interestingly, BMP4 treatment reduced MMP13 in the mutants but did not affect WT (<xref ref-type="fig" rid="fig5">Figure 5C</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). A principle component analysis (PCA) of the RNA sequencing data revealed that the WT line was overall more sensitive to BMP4, as indicated by the arrows (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Given that the BMP4-treated WT chondrocytes had the most apparent hypertrophic phenotype, later analyses were performed comparing the BMP4- and TGFβ3-treated chondrocytes for simplification.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Wildtype (WT) chondrocytes are more sensitive to BMP4 treatment.</title><p>(<bold>A</bold>) WT chondrocytes treated with BMP4 developed a hypertrophic phenotype with enlarged lacunae, which was not present in the mutant cell lines or other conditions, as shown by Safranin-O and hematoxylin staining. Scale bar = 500 µm. Representative images from 2 experiments. (<bold>B</bold>) Cell diameter was significantly increased in the WT with BMP4 treatment compared to all other groups indicating a hypertrophic phenotype. Mean ± standard error of the mean (SEM). <italic>n</italic> = 249–304 cells from 2 pellets. Different letters indicate statistical significance (p &lt; 0.05) between groups as determined by Kruskal–Wallis test with multiple comparisons since data was not normally distributed. (<bold>C</bold>) Western blot shows that WT had a stronger increased production of ALPL, COL10A1, IHH, RUNX2, and RUNX2-9 in response to BMP4 treatment than the mutants. (<bold>D</bold>) Principle component analysis (PCA) of bulk RNA-seq reveals an increased sensitivity to BMP4 (and TGFβ3 + BMP4) treatment in WT human-induced pluripotent stem cell (hiPSC)-derived chondrocytes compared to V620I and T89I. <italic>n</italic> = 3–4 samples.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>ALPL western blot: the full raw unedited gel with and without the bands labeled.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-71154-fig5-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>COL10A1 western blot: the full raw unedited gel with and without the bands labeled.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-71154-fig5-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>IHH western blot: the full raw unedited gel with and without the bands labeled.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-71154-fig5-data3-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5—source data 4.</label><caption><title>MMP13 western blot: the full raw unedited gel with and without the bands labeled.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-71154-fig5-data4-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata5"><label>Figure 5—source data 5.</label><caption><title>RUNX2 western blot: the full raw unedited gel with and without the bands labeled.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-71154-fig5-data5-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata6"><label>Figure 5—source data 6.</label><caption><title>GAPDH western blot: the full raw unedited gel with and without the bands labeled.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-71154-fig5-data6-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-71154-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Hypertrophic gene and protein expression.</title><p>(<bold>A</bold>) The full images of the ALPL, COL10A1, IHH, MMP13, RUNX2, RUNX2-9, and GAPDH western blots. (<bold>B</bold>) Quantification of the western blots. (<bold>C</bold>) Gene expression from RNA sequencing for the same genes. For simplicity, TGFβ3- and BMP4-treated groups were included in the graphs. Mean ± <italic>n</italic> = 3–4. *p &lt; 0.05. Significance determined by Student’s <italic>t</italic>-test comparing TGFβ3- and BMP4-treated groups within the cell line and one-way analysis of variance (ANOVA) with Tukey’s post hoc test comparing cell lines within BMP4-treated group.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-71154-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Hierarchical <italic>k</italic>-means clustering of gene expression profiles of BMP4- and TGFβ3-treated chondrocytes resulted in 9 unique clusters, as determined using the gap statistics method (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Most of the clusters, including the largest (i.e., cluster 1), showed up-regulation of gene expression with BMP4 treatment, while clusters 4, 5, and 9 showed down-regulation. The gene expression per group for each cluster is listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Overall, WT responded to BMP4 treatment with the largest number of DEGs, over 2500, with only 22% of them shared among all three lines (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Although cluster 1 shows an overall increase in gene expression with BMP4 treatment, WT had a larger increase in expression than the mutants (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). In fact, some of the genes that were up-regulated with BMP4 treatment in WT may have no change or down-regulation in mutants (cluster 1, <xref ref-type="fig" rid="fig6">Figure 6A</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>V620I and T89I had an inhibited hypertrophic response to BMP4 treatment.</title><p>(<bold>A</bold>) There are 9 clusters of genes based on expression and hierarchical <italic>k</italic>-means clustering of the samples. (<bold>B</bold>) Venn diagram shows similar and distinct differentially expressed genes (DEGs) in response to BMP4 treatment in all three lines. (<bold>C</bold>) Cluster 1 represented increasing in expression from TGFβ3 to BMP4 treatment (left to right on <italic>x</italic>-axis). <italic>Y</italic>-axis scale (−1.5 to 2) represents the scaled mean counts. (<bold>D</bold>) A protein–protein interaction network with functional enrichment analysis of cluster 1 reveals the top regulating genes and their associated concepts. Connections between protein-coding genes and Gene Ontology (GO) processes are based on the average log fold change between cell lines. Coloring of the protein-coding gene circles is divided into three to represent the log fold change for each cell line as shown in the legend. The white arrows in the legend indicates the location of the maximum log fold change for each respective cell line. The gray boxes represent the top 5 GO terms (biological process) identified for the network with the log<sub>10</sub>(false discovery rate) underneath the term. (<bold>E</bold>) A heatmap of the top 25 up-regulated genes, and their log<sub>2</sub> fold change, in each line compared to their respective TGFβ3 controls. (<bold>F</bold>) The top GO terms and biological pathways associated with the up-regulated DEGs with BMP4 treatment. Symbol color represents the cell line, and size represents the −log<sub>10</sub>(p<sub>adj</sub>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-71154-fig6-v2.tif"/></fig><p>As cluster 1 represents the primary response to BMP4 treatment and may highlight how the TRPV4 mutations inhibit chondrocyte hypertrophy, we constructed a gene network of this cluster (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). The log fold change of each gene per cell line is represented by a color scale, which is consistent with WT having overall higher expression of the genes (as indicated by the white arrows in the legend; <xref ref-type="fig" rid="fig6">Figure 6D</xref>). With GO term analysis, the cluster 1 gene network is highly associated with ossification, biomineral tissue development, skeletal system development, tissue development, and osteoblast differentiation (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Alkaline phosphatase, biomineralization associated (<italic>ALPL</italic>), amelogenin X-linked (<italic>AMELX</italic>), fibroblast growth factor receptor 3 (<italic>FGFR3</italic>), interferon-induced transmembrane protein 5 (<italic>IFITM5</italic>), Indian hedgehog (<italic>IHH</italic>), parathyroid hormone 1 receptor (<italic>PTH1R</italic>), and noggin (<italic>NOG</italic>) were connected to at least 4 of the top 5 GO terms. Of those, <italic>ALPL</italic>, <italic>AMELX</italic>, and <italic>IFITM5</italic> showed much higher expression in WT than the mutants alongside antioxidant glutathione <italic>S</italic>-transferase alpha 1 (<italic>GSTA1</italic>) and bone ECM proteins integrin-binding sialoprotein (<italic>IBSP</italic>) and matrix extracellular phosphoglycoprotein (<italic>MEPE</italic>). Lack of expression of these key genes, particularly <italic>ALPL</italic>, may be responsible for the inhibited hypertrophy in TRPV4 V620I- and T89I-mutated chondrocytes.</p><p>We next investigated and plotted the top 25 up-regulated genes for each line with BMP4 treatment (compared to their respective TGFβ3 control) (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). 88% of these genes were also present in cluster 1. The key genes <italic>ALPL</italic>, <italic>AMELX</italic>, <italic>IFITM5</italic>, <italic>GSTAI</italic>, <italic>IBSP,</italic> and <italic>MEPE</italic> had distinctly higher expression in WT than mutants, in agreement with the network analysis. Both mutants showed higher expression than WT of ankyrin repeat and SOCS box containing 10 (<italic>ASB10</italic>), GTPase, IMAP family member 6 (<italic>GIMAP6</italic>), and adhesion G-protein-coupled receptor D1 (<italic>ADGRD1</italic>) when compared to their corresponding TGFβ3 control group. GO term analysis was further performed on all BMP4 up-regulated DEGs for each line (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). WT was highly associated with skeletal system development, ossification, endochondral ossification, and extracellular structure organization. V620I was also associated with these concepts to a lesser degree, while T89I showed little to no association. We believe these results highlight that the TRPV4 mutations reduce BMP4-induced hypertrophy but to a greater extent with the T89I mutation, which causes the more severe phenotype.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>To elucidate the detailed molecular mechanisms underlying the distinct severity of skeletal dysplasias caused by two TRPV4 mutations (moderate brachyolmia-causing V620I vs. severe metatropic dysplasia-causing T89I), we used CRISPR-Cas9 gene editing to generate hiPSC-derived chondrocytes bearing either V620I or T89I mutation. We observed that day-28 chondrocytes exhibited differences in channel function and gene expression between the mutants and WT control. Differences in transcriptomic profiles between V620I and T89I and from WT became more apparent with maturation following 4 additional weeks of culture with TGFβ3 or hypertrophic differentiation with BMP4 treatment. Of note, WT was significantly more sensitive to BMP4-induced hypertrophy. At the transcriptomic and proteomic levels, TRPV4 mutations inhibited chondrocyte hypertrophy, particularly with the T89I mutation, whereas V620I exhibited a milder phenotype, consistent with the clinical presentation of these two conditions. Our results suggest that skeletal dysplasias may be, at least in part, resulting from improper chondrocyte hypertrophy downstream of altered TRPV4 function. Furthermore, with our genome-wide RNA sequencing analysis, we also identified several putative genes that may be responsible for these dysregulated pathways in human chondrocytes bearing V620I or T89I TRPV4 mutations.</p><p>Our findings are generally consistent with previous non-human models of V620I and T89I mutations. Two other models that have studied the V620I and T89I mutations include <italic>X. laevis</italic> oocytes injected with rat TRPV4 cRNA (<xref ref-type="bibr" rid="bib55">Loukin et al., 2011</xref>) or primary porcine chondrocytes transfected with human mutant TRPV4 (<xref ref-type="bibr" rid="bib47">Leddy et al., 2014b</xref>). Both reports and our current study investigated the baseline currents of the mutant TRPV4 compared to WT. Here, we used patch clamping and observed high basal currents in V620I with a significant decrease when TRPV4 was inhibited. However, this characteristic was trending, but not significant, in T89I, despite both V620I and T89I being reported as gain-of-function mutations (<xref ref-type="bibr" rid="bib8">Camacho et al., 2010</xref>; <xref ref-type="bibr" rid="bib86">Rock et al., 2008</xref>). Both the <italic>X. laevis</italic> oocyte and porcine chondrocyte models confirmed high basal currents through V620I-TRPV4 (<xref ref-type="bibr" rid="bib47">Leddy et al., 2014b</xref>; <xref ref-type="bibr" rid="bib55">Loukin et al., 2011</xref>). Interestingly, <italic>X. laevis</italic> oocytes, but not the humanized porcine chondrocytes, showed an increase in basal Ca<sup>2+</sup> signaling through T89I (<xref ref-type="bibr" rid="bib47">Leddy et al., 2014b</xref>; <xref ref-type="bibr" rid="bib55">Loukin et al., 2011</xref>). Furthermore, our results were consistent with a summary of TRPV4 channelopathies reporting an increase in conductivity in V620I but no change in T89I (<xref ref-type="bibr" rid="bib39">Kang, 2012</xref>). Interestingly, V620I also had increased expression of <italic>PRKCA</italic>, the gene encoding for protein kinase C alpha. Phosphorylation by PKC has been shown to alter TRPV4 activation (<xref ref-type="bibr" rid="bib9">Cao et al., 2018</xref>) and therefore may play a role in the altered signaling with these mutations. In future experiments, we will further investigate PKC and PKA phosphorylation of TRPV4 and the effects on channel activity in these mutations. The conflicting basal current results could be due to differences in phosphorylation or the species of the TRPV4, but this was not the case regarding channel activation. As mentioned, the hiPSC-derived chondrocytes with V620I and T89I TRPV4 had reduced currents and Ca<sup>2+</sup> signaling in response to chemical agonist GSK101. However, our previous study showed the porcine chondrocytes with mutant human TRPV4 had increased peak Ca<sup>2+</sup> signaling in response to hypotonic changes (<xref ref-type="bibr" rid="bib47">Leddy et al., 2014b</xref>). This discrepancy could be due to the mode of activation of TRPV4 (i.e., osmotic vs. chemical agonist). In contrast, the oocytes with mutant rat TRPV4 had lower currents in response to both hypotonic and chemical (GSK101) TRPV4 activation compared to WT-TRPV4, consistent with our findings. It can be speculated that there is decreased sensitivity to the antagonist because the mutated hiPSC-derived chondrocytes are compensating for the increased basal activity by reducing the number of TRPV4 channels or other ion channels and signaling transducers as shown with the RNAseq data and associated GO terms. The increased basal currents and decreased channel sensitivity to TRPV4 agonist GSK101 with mutated TRPV4 are also likely resulting from an increased open probability of TRPV4 making the channels less likely to be activated by a chemical agonist (<xref ref-type="bibr" rid="bib55">Loukin et al., 2011</xref>). The obvious differences in both resting and activated states confirm functional differences with TRPV4 mutations that may ultimately lead to changes in downstream signaling of the channel, which alter joint development and result in skeletal dysplasias.</p><p>It was hypothesized, in the porcine chondrocyte study, that the increased Ca<sup>2+</sup> signaling due to the V620I and T89I TRPV4 mutations increased <italic>FST</italic> expression that inhibited BMP signaling and hypertrophy (<xref ref-type="bibr" rid="bib46">Leddy et al., 2014a</xref>; <xref ref-type="bibr" rid="bib47">Leddy et al., 2014b</xref>). Surprisingly, we found no differences in <italic>FST</italic> expression in mutant hiPSC-derived chondrocytes compared to WT. However, our previous study used non-human cells, which could alter the effects of the human TRPV4 mutations and downstream gene expression. Another previous hypothesis made was that the altered TRPV4 signaling increased <italic>SOX9</italic> expression, a known regulator of resting and proliferating chondrocytes up-regulated by TRPV4 activation (<xref ref-type="bibr" rid="bib67">Muramatsu et al., 2007</xref>), thus decreasing hypertrophy (<xref ref-type="bibr" rid="bib86">Rock et al., 2008</xref>). <italic>SOX9</italic>-knockin mice exhibit a dwarfism phenotype (<xref ref-type="bibr" rid="bib4">Amano et al., 2009</xref>), and <italic>SOX9</italic> overexpression inhibits hypertrophy and endochondral ossification (<xref ref-type="bibr" rid="bib30">Hattori et al., 2010</xref>; <xref ref-type="bibr" rid="bib58">Lui et al., 2019</xref>), likely via parathyroid hormone-related protein (PTHrP) (<xref ref-type="bibr" rid="bib4">Amano et al., 2009</xref>; <xref ref-type="bibr" rid="bib72">Nishimura et al., 2012b</xref>). However, PTHrP was not strongly regulated in our data set. Furthermore, our RT-qPCR revealed that only V602I significantly up-regulated <italic>SOX9</italic>, and the RNAseq data showed that <italic>SOX9</italic> had a smaller fold change compared to other chondrogenic genes, such as <italic>GDF5</italic>, <italic>COL6A1</italic>, <italic>COL6A3</italic>, and <italic>COMP</italic>. In fact, these genes, which were up-regulated in V620I- and T89I-hiPSC-derived chondrocytes, have a pro-chondrogenic but anti-hypertrophic phenotype (<xref ref-type="bibr" rid="bib10">Caron et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Chu et al., 2017</xref>; <xref ref-type="bibr" rid="bib32">Hecht and Sage, 2006</xref>). Therefore, these results suggest additional and alternative pathways to <italic>FST</italic> and <italic>SOX9</italic> that are responsible for the V620I and T89I skeletal dysplasias.</p><p>Our results are generally consistent with previous reports on the effects of other TRPV4 mutations such as lethal and non-lethal metatropic dysplasia-causing I604M (<xref ref-type="bibr" rid="bib87">Saitta et al., 2014</xref>) and L619F (<xref ref-type="bibr" rid="bib73">Nonaka et al., 2019</xref>). The data also reveal potential differences in the effects of these varying TRPV4 mutations on cell electrophysiology or differentiation. For example, we saw an increase in <italic>SOX9</italic> expression in V620I, while no change in T89I. Gain-of-function mutation L619F also increased <italic>SOX9</italic> expression (<xref ref-type="bibr" rid="bib73">Nonaka et al., 2019</xref>), while I604M, which has been reported to not alter conductivity like T89I (<xref ref-type="bibr" rid="bib39">Kang, 2012</xref>), decreased <italic>SOX9</italic> expression (<xref ref-type="bibr" rid="bib87">Saitta et al., 2014</xref>). I604M also decreased <italic>COL2A1</italic>, <italic>COL10A1</italic>, and <italic>RUNX2</italic> expression consistent with our T89I results (<xref ref-type="bibr" rid="bib87">Saitta et al., 2014</xref>). Intriguingly, the L619F mutation was reported to increase Ca<sup>2+</sup> signaling with activation via a TRPV4 agonist (<xref ref-type="bibr" rid="bib73">Nonaka et al., 2019</xref>). However, we observed that V620I and T89I had significantly reduced Ca<sup>2+</sup> signaling compared to WT in response to chemical agonist GSK101, as confirmed by both confocal imaging and patch clamping. These results highlight that TRPV4 mutations have heterogeneous effects on downstream signaling pathways and thus lead to diverse disease phenotypes, despite similar classification of these mutations as ‘gain-of-function’. It is also important to note that in previous studies, chondrogenic differentiation of iPSCs (<xref ref-type="bibr" rid="bib87">Saitta et al., 2014</xref>) or dental pulp cells (<xref ref-type="bibr" rid="bib73">Nonaka et al., 2019</xref>) were performed in short-term micromass culture, and not long-term pellet culture as in our study, potentially leading to different levels of chondrogenesis and maturation of the cells.</p><p>Our transcriptomic analysis showed significant changes in various <italic>HOX</italic> family genes due to TRPV4 mutations, suggesting a potential role of these genes in maintaining the immature, chondrogenic phenotype in the mutated lines. At both days 28 and 56, the top 25 up-regulated genes in the V620I and T89I lines included genes from the anterior <italic>HOX</italic> family (<xref ref-type="bibr" rid="bib37">Iimura and Pourquié, 2007</xref>; <xref ref-type="bibr" rid="bib88">Seifert et al., 2015</xref>). The high expression of anterior <italic>HOX</italic> genes indicates that the mutants are maintaining the chondrocytes in an early developmental stage with axial patterning. At days 28 and 56, <italic>HOXA2</italic>, <italic>HOXA3</italic>, and <italic>HOXA4</italic> were in the top up-regulated genes, with <italic>HOXA4</italic> having the largest fold change. Interestingly, gain-of-function mutations or overexpression of <italic>HOXA2</italic>, <italic>HOXA3</italic>, and <italic>HOXA4</italic> impair chondrogenesis, limit skeletal development, decrease endochondral ossification regulators, and delay mineralization in animal models (<xref ref-type="bibr" rid="bib16">Creuzet et al., 2002</xref>; <xref ref-type="bibr" rid="bib19">Deprez et al., 2013</xref>; <xref ref-type="bibr" rid="bib42">Kanzler et al., 1998</xref>; <xref ref-type="bibr" rid="bib51">Li and Cao, 2006</xref>; <xref ref-type="bibr" rid="bib60">Massip et al., 2007</xref>; <xref ref-type="bibr" rid="bib88">Seifert et al., 2015</xref>). <italic>HOXA5</italic> was also highly up-regulated at both days 28 and 56, and mutations in this gene showed disordered patterning of limb bud development (<xref ref-type="bibr" rid="bib80">Pineault and Wellik, 2014</xref>). Finally, the rib and spine phenotypes associated with brachyolmia and metatropic dysplasia could be contributed to the altered expression of <italic>HOXA4</italic> to <italic>HOXA7</italic> as it has been shown that these genes are associated with rib and spine patterning, and alterations in expression have led to defects (<xref ref-type="bibr" rid="bib11">Chen et al., 1998</xref>; <xref ref-type="bibr" rid="bib101">Wellik, 2009</xref>). The only up-regulated posterior <italic>HOX</italic> genes were <italic>HOXC8</italic> and <italic>HOXD8</italic> at day 56 (<xref ref-type="bibr" rid="bib37">Iimura and Pourquié, 2007</xref>; <xref ref-type="bibr" rid="bib88">Seifert et al., 2015</xref>). The absence of posterior <italic>HOX9</italic>, <italic>HOX11</italic>, and <italic>HOX13</italic>, which are associated with limb development and hypertrophic <italic>RUNX2/3</italic> expression (<xref ref-type="bibr" rid="bib80">Pineault and Wellik, 2014</xref>; <xref ref-type="bibr" rid="bib83">Qu et al., 2020</xref>), may be at least partially responsible for the improper development in skeletal dysplasias. Interestingly, many links have been identified between <italic>HOX</italic> genes and TGFβ3-family signaling, specifically through SMAD proteins, both within skeletal development and other processes (e.g., murine lung development) (<xref ref-type="bibr" rid="bib51">Li and Cao, 2006</xref>; <xref ref-type="bibr" rid="bib50">Li and Cao, 2003</xref>; <xref ref-type="bibr" rid="bib97">Volpe et al., 2013</xref>).</p><p>In fact, TRPV4 and TGF-β signaling have recently been shown to interact, with effects specific to the order in which they occur (<xref ref-type="bibr" rid="bib70">Nims et al., 2021</xref>; <xref ref-type="bibr" rid="bib74">O’Conor et al., 2014</xref>; <xref ref-type="bibr" rid="bib105">Woods et al., 2021</xref>). Consistent with previous finding with hiPSCs housing the I604M TRPV4 mutations (<xref ref-type="bibr" rid="bib87">Saitta et al., 2014</xref>), the altered TRPV4 activity in our hiPSC-derived chondrocytes could be altering their response to the TGFβ3 and BMP4 treatments. Furthermore, the V620I and T89I mutations increased expression of <italic>HTRA1</italic>, which has been shown to bind to and alter the response to members of the TGFβ family (<xref ref-type="bibr" rid="bib81">Polur et al., 2010</xref>). Furthermore, <italic>TGFβ3</italic> and <italic>TWIST</italic>, which is downstream of TGFβ3 signaling, were both up-regulated in TRPV4-mutated hiPSC-derived chondrocytes. It has been reported that <italic>TGFB3</italic> expression and signaling prevent osteoblastogenesis of mesenchymal stem cells (<xref ref-type="bibr" rid="bib71">Nishimura et al., 2012a</xref>; <xref ref-type="bibr" rid="bib72">Nishimura et al., 2012b</xref>), while <italic>TWIST</italic> inhibits hypertrophy regulators <italic>RUNX2</italic> and <italic>FGFR2</italic> (<xref ref-type="bibr" rid="bib62">Michigami, 2014</xref>; <xref ref-type="bibr" rid="bib64">Miraoui and Marie, 2010</xref>). Therefore, another mechanism of hypertrophic dysregulation with these mutations could be altered response to TGFβ family signaling.</p><p>In fact, in response to treatment with BMP4, a member of the TGFβ family, there was increased expression of <italic>GSTA1</italic>, which produces the antioxidant glutathione (<xref ref-type="bibr" rid="bib12">Chen et al., 2008</xref>; <xref ref-type="bibr" rid="bib31">Hayes et al., 2005</xref>), in WT but not in mutants. BMP4 treatment of T89I-mutated chondrocytes significantly increased expression of another antioxidant catalase (<italic>CAT</italic>) compared to its TGFβ3 control group; however, TRPV4-mutated chondrocytes without BMP4 treatment had significantly lower <italic>CAT</italic> expression. This may potentially indicate an association between antioxidants, which remove reactive oxygen species (ROS; e.g., H<sub>2</sub>O<sub>2</sub>), and chondrocyte maturation. While one study observed that chondrocyte maturation is associated with decreasing catalase (<xref ref-type="bibr" rid="bib66">Morita et al., 2007</xref>), this is inconsistent with other findings. Another report stated hypoxia, which increases ROS, inhibits hypertrophic differentiation and endochondral ossification (<xref ref-type="bibr" rid="bib49">Leijten et al., 2012</xref>). Many others found that ROS prevent endochondral ossification, potentially via inhibition of the hedgehog pathways (<xref ref-type="bibr" rid="bib6">Atashi et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2008</xref>; <xref ref-type="bibr" rid="bib26">Fragonas et al., 1998</xref>). Interestingly, <italic>IHH</italic> also had the lowest expression level in our T89I mutant chondrocytes. These findings suggest that decreased expression of <italic>CAT</italic> and <italic>GSTA1</italic> in TRPV4 mutants may also be involved in dysregulating endochondral ossification in these cells.</p><p><italic>GSTA1</italic> is one of many genes with significantly lower expression in mutated chondrocytes compared to WT in response to BMP4 treatment including <italic>ALPL</italic>, <italic>AMELX</italic>, <italic>IFITM5</italic>, <italic>IBSP</italic>, and <italic>MEPE</italic>. These genes play important roles in bone development. For example, <italic>IBSP</italic> is downstream of <italic>RUNX2</italic>, a primary transcription factor of hypertrophic differentiation and osteoblast differentiation (<xref ref-type="bibr" rid="bib44">Komori, 2018</xref>). Further, <italic>MEPE</italic> negatively (<xref ref-type="bibr" rid="bib57">Lu et al., 2004</xref>; <xref ref-type="bibr" rid="bib91">Staines et al., 2012</xref>) and <italic>IFITM5</italic> (<xref ref-type="bibr" rid="bib28">Hanagata et al., 2011</xref>; <xref ref-type="bibr" rid="bib65">Moffatt et al., 2008</xref>) and <italic>ALPL</italic> (<xref ref-type="bibr" rid="bib63">Millán, 2013</xref>; <xref ref-type="bibr" rid="bib92">Strzelecka- Kiliszek et al., 2018</xref>) positively regulate bone mineralization during skeletogenesis, respectively. Mutations in these genes also lead to bone mineralization diseases such as rickets (<xref ref-type="bibr" rid="bib57">Lu et al., 2004</xref>; <xref ref-type="bibr" rid="bib91">Staines et al., 2012</xref>), osteogenesis imperfecta (<xref ref-type="bibr" rid="bib29">Hanagata, 2016</xref>), and hypophosphatasia with deformed long bones (<xref ref-type="bibr" rid="bib94">Taillandier et al., 2015</xref>). Not only did we observe significantly lower gene expression of <italic>ALPL</italic> in TRPV4-mutated chondrocytes treated with BMP4; we also demonstrated that ALPL protein production is negatively associated with disease severity. Our results indicate that not only do the mutated cells have an altered hypertrophic response to BMP4, but there is a connection between these genes, particularly <italic>ALPL</italic>, or tissue-nonspecific alkaline phosphatase, and delayed endochondral ossification in chondrocytes bearing V620I or T89I mutations. However, how these genes and their transcription are associated with TRPV4 function and mutations still warrants further investigation.</p><p>The gene expression and protein production of <italic>ALPL</italic>, as well as <italic>IHH</italic>, in response to BMP4 treatment was not only significantly lower in mutants compared to WT, but it was also significantly lower for the severe T89I mutation compared to the moderate V620I mutation. This is one of the many targets showing the different levels of genetic and protein production between the two mutations that may be responsible for the distinct severity and phenotype of the corresponding diseases. Furthermore, several other genes were also detected to be uniquely up- or down-regulated compared to WT in one mutated line but not the other. Interestingly, there were more uniquely expressed genes between the two mutated lines at day 56, suggesting the separation of transcriptomic profiles in V620I and T89I occurs at later time points of chondrocyte maturity. Among those unique to severe T89I include down-regulation of <italic>IBSP</italic>, a positive mineralization regulator, at day 28, and up-regulation of negative regulator <italic>MEPE</italic> at day 56. These unique genes were also not associated with many of the same biological processes as WT and V620I, especially those regarding endochondral ossification, when treated with BMP4. This, in conjunction with the high number of unique DEGs, represents a potential inhibition of hypertrophy, particularly in response to BMP4 treatment, with the T89I mutation leading to severe metatropic dysplasia. V620I also had unique differences from both WT and T89I. The decrease in mechanical properties with increased basal current of the V620I mutant was unexpected since TRPV4 activation was previously shown to increase matrix production and properties (<xref ref-type="bibr" rid="bib74">O’Conor et al., 2014</xref>). Furthermore, genes uniquely up-regulated in V620I were associated with interferon type I (IFNβ). IFNβ has been reported to decrease inflammatory markers and matrix degradation (<xref ref-type="bibr" rid="bib34">Hu et al., 2005</xref>; <xref ref-type="bibr" rid="bib77">Palmer et al., 2004</xref>; <xref ref-type="bibr" rid="bib96">van Holten et al., 2004</xref>; <xref ref-type="bibr" rid="bib110">Zhao et al., 2014</xref>), despite the decrease in moduli observed in the day-42 V620I chondrogenic pellets. Interestingly, a study comparing bone marrow-derived MSCs from healthy and systemic lupus erythematous patients found that IFNβ-inhibited osteogenesis via suppression of <italic>RUNX2</italic> and other osteogenic genes (<xref ref-type="bibr" rid="bib27">Gao et al., 2020</xref>). Highlighting a potential, unique regulator of the delayed hypertrophy in V620I leading to brachyolmia.</p><p>Here, we present multiple putative genes and pathways that could be involved in delaying, and potentially inhibiting, chondrocyte hypertrophy in V620I- and T89I-TRPV4 mutants. It should be noted, however, that this study has some potential limitations. It is well-recognized that Wnt/β-catenin signaling plays an important role in chondrocyte hypertrophy (<xref ref-type="bibr" rid="bib33">Hou et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Huang et al., 2018</xref>; <xref ref-type="bibr" rid="bib62">Michigami, 2014</xref>). After 56 days of differentiation, we observed increased expression of β-catenin-coding gene <italic>CTNNB1</italic> in T89I-mutated chondrocytes highlighting this pathway could be playing a role in the inhibited hypertrophy. However, we may be preventing some hypertrophy since our chondrogenic protocol uses a pan-Wnt inhibitor to prevent off-target differentiation and promote a homogenous chondrocyte population (<xref ref-type="bibr" rid="bib106">Wu et al., 2021</xref>). Nevertheless, our WT chondrocytes, but not TRPV4 mutants, exhibited hypertrophic differentiation with BMP4 treatment, suggesting that DEGs/pathways detected in our sequencing analysis are still robust. Since this study focuses on TRPV4 gain-of-function mutations, future studies could fully or partially inhibit TRPV4 signaling to determine if that would increase similarity between the mutant and WT lines at various stages of chondrogenic and hypertrophic differentiation. Additionally, this study only activated TRPV4 using the pharmacological activator GSK101. Other future experiments could activate the channel osmotically or with mechanical loading to investigate additional differences in TRPV4 function leading to skeletal dysplasias during development.</p><p>In summary, our study found that dysregulated skeletal development in the V620I- and T89I-TRPV4 dysplasias is likely due, at least in part, to delayed and inhibited chondrocyte hypertrophy. The gain-of-function mutations may lead to increased <italic>HOX</italic> gene expression, altered TGFβ signaling, decreased hypertrophic and biomineralization gene expression (e.g., <italic>ALPL</italic>, <italic>AMELX</italic>, <italic>IFITM5</italic>, <italic>IBSP</italic>, and <italic>MEPE</italic>), and genes regulating hedgehog pathways and ROS accumulation (e.g., <italic>GSTA1</italic> and <italic>CAT</italic>). Our findings lay a foundation for the development of therapeutics for these diseases and provide significant insights into the regulation of endochondral ossification via TRPV4.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>hiPSC culture</title><p>The BJFF.6 (BJFF) human iPSC line (Washington University Genome Engineering and iPSC Center [GEiC], St. Louis, MO), was used in this study as the isogenic WT control. CRISPR-Cas9 gene editing was used to create the V620I and T89I mutations in the BJFF cell line as described previously (<xref ref-type="bibr" rid="bib2">Adkar et al., 2019</xref>). All three lines underwent STR profiling for cell line authentication and were verified to have no cross-contamination with other cell lines. All cells tested negative for mycoplasma. The hiPSCs were maintained on vitronectin (VTN-N; cat. num. A14700; Thermo Fisher Scientific, Waltham, MA)-coated plates in Essential 8 Flex medium (E8; cat. num. A2858501; Gibco, Thermo Fisher Scientific, Waltham, MA). Medium was changed daily until cells were passaged at 80–90% confluency (medium supplemented with Y-27632 [cat. num. 72304; STEMCELL Technologies, Vancouver, Canada] for 24 hr) or induced into mesodermal differentiation at 30–40% confluency.</p></sec><sec id="s4-2"><title>Mesodermal differentiation</title><p>The hiPSCs were differentiated through the mesodermal pathway as previously described (<xref ref-type="bibr" rid="bib2">Adkar et al., 2019</xref>; <xref ref-type="bibr" rid="bib20">Dicks et al., 2020</xref>; <xref ref-type="bibr" rid="bib106">Wu et al., 2021</xref>). In brief, cells were fed daily with different cocktails of growth factors and small molecules for 12 days in mesodermal differentiation medium and driven through the anterior primitive streak (1 day; 30 ng/ml Activin [cat. num. 338-AC; R&amp;D Systems, Minneapolis, MN], 20 ng/ml FGF2 [cat. num. 233-FB-025/CF; R&amp;D Systems, Minneapolis, MN], 4 µM CHIR99021 [cat. num. 04-0004-02; Reprocell, Beltsville, MD]), paraxial mesoderm (1 day; 20 ng/ml FGF2, 3 µM CHIR99021, 2 µM SB505124 [cat. num. 3263; Tocris Bioscience, Bristol, UK], 4 µM dorsomorphin [DM; cat. num. 04-0024; Reprocell, Beltsville, MD]), early somite (1 day; 2 µM SB505124, 4 µM dorsomorphin, 500 nM PD173074 [cat. num. 3044; Tocris Bioscience, Bristol, UK], 1 µM Wnt-C59 [cat. num. C7641-2s; Cellagen Technologies, San Diego, CA]), and sclerotome (3 days; 1 µM Wnt-C59, 2 µM purmorphamine [cat. num. 04-0009; Reprocell, Beltsville, MD]) into chondroprogenitor cells (6 days; 20 ng/ml BMP4 [cat. num. 314-BP-010CF; R&amp;D Systems, Minneapolis, MN]). Mesodermal differentiation medium had a base of Iscove’s Modified Dulbecco’s Medium, glutaMAX (IMDM; cat. num. 31980097; Gibco, Thermo Fisher Scientific, Waltham, MA) and Ham’s F-12 nutrient mix, glutaMAX (F12; cat. num. 31765092; Gibco, Thermo Fisher Scientific, Waltham, MA) in equal parts supplemented with 1% penicillin–streptomycin (P/S; cat. num. 15140122; Gibco, Thermo Fisher Scientific, Waltham, MA), 1% Insulin–Transferrin–Selenium (ITS+; cat. num. 41400045; Gibco, Thermo Fisher Scientific, Waltham, MA), 1% chemically defined concentrated lipids (cat. num. 11905031; Thermo Fisher Scientific, Waltham, MA), and 450 µM 1-thioglycerol (cat. num. M6145; Millipore Sigma, St. Louis, MO). The chondroprogenitor cells were then disassociated for chondrogenic differentiation.</p></sec><sec id="s4-3"><title>Chondrogenic differentiation with 3D pellet culture</title><p>Cells were differentiated into chondrocytes using a high-density, suspension pellet culture (<xref ref-type="bibr" rid="bib2">Adkar et al., 2019</xref>; <xref ref-type="bibr" rid="bib20">Dicks et al., 2020</xref>; <xref ref-type="bibr" rid="bib106">Wu et al., 2021</xref>). In summary, cells were resuspended in chondrogenic medium: Dulbecco’s Modified Eagle Medium/F12, glutaMAX (DMEM/F12; cat. num. 10565042; Gibco, Thermo Fisher Scientific, Waltham, MA), 1% P/S, 1% ITS+, 1% Modified Eagle Medium (MEM) with nonessential amino acids (NEAA; cat. num. 11140050; Gibco, Thermo Fisher Scientific, Waltham, MA), 0.1% dexamethasone (Dex; cat. num. D4902; Millipore Sigma, St. Louis, MO), and 0.1% 2-Mercaptoethnol (2-ME; cat. num. 21985023; Gibco, Thermo Fisher Scientific, Waltham, MA) supplemented with 0.1% <sc>L</sc>-ascorbic acid (ascorbate; cat. num. A8960; Millipore Sigma, St. Louis, MO), 0.1% <sc>L</sc>-proline (proline; cat. num. P5607; Millipore Sigma, St. Louis, MO), 10 ng/ml human transforming growth factor- β3 ( TGFβ3; cat. num. 243-B3-010/CF; R&amp;D Systems, Minneapolis, MN), 1 µM Wnt-C59, and 1 µM ML329 (cat. num. 22481; Cayman Chemical, Ann Arbor, MI) at 5 × 10<sup>5</sup> cells/ml. One mL of the cell solution was added to a 15-ml conical tube (cat. num. 430790; Corning, Corning, NY) and centrifuged to form the spherical pellets. Pellets were fed every 3–4 days with complete chondrogenic medium until the desired time point. Several time points of the chondrogenic pellets were used to study chondrocyte maturation (7, 14, 28, and 42 days), mechanical properties (28 and 42 days), hypertrophy (28 days) or, after digestion to single-cell day-28 chondrocytes, on Ca<sup>2+</sup> signaling in response to pharmacological activation of TRPV4.</p></sec><sec id="s4-4"><title>BMP4 treatment to promote hypertrophic differentiation</title><p>Some day-28 pellets were also further differentiated for an additional 4 weeks to examine the effects of the mutations on chondrocyte hypertrophy. Pellets were cultured with complete chondrogenic medium with either TGFβ3 (10 ng/ml) alone, BMP4 (50 ng/ml) alone, or a combination of TGFβ3 (10 ng/ml) and BMP4 (50 ng/ml).</p></sec><sec id="s4-5"><title>Dissociation of chondrogenic pellets to obtain single-cell hiPSC-derived chondrocytes</title><p>To isolated hiPSC-derived chondrocytes, day-28 chondrogenic pellets were rinsed and placed in an equal volume (1 pellet per 1 ml) of digestion medium (0.4% wt/vol type II collagenase [cat. num. LS00417; Worthington Biochemical, Lakewood, NJ] in DMEM/F12 with 10% fetal bovine serum [FBS; cat. num. S11550; Atlanta Biologicals, R&amp;D Systems, Minneapolis, MN]). The tubes were placed on an orbital shaker at 37°C and vortexed every 20 min for approximately 2 hr. Once the tissue was digested and could no longer be seen by the naked eye, the digestion medium was neutralized in DMEM/F12 medium containing 10% FBS. These cells were used for patch clamping and confocal experiments.</p></sec><sec id="s4-6"><title>TRPV4 agonists and antagonists</title><p>Solutions were prepared immediately before experiments and held at room temperature. GSK1016790A (GSK101; cat. num. G0798; Sigma-Aldrich, St. Louis, MO) and/or GSK205 (cat. num. AOB1612 1263130-79-5; AOBIOUS, Gloucester, MA), in addition to dimethyl sulfoxide (DMSO) for a vehicle control, were added to assay buffer (Hanks’ Balanced Salt Solution [HBSS; cat. num. 14025076; Gibco, Thermo Fisher Scientific, Waltham, MA] with 2% N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) [cat. num. 15630130; Gibco, Thermo Fisher Scientific, Waltham, MA]) at 2-folds of the desired concentration (20 nM GSK101, 40 µM GSK205). Solutions were made at 2-folds of the desired concentration because they would be mixed at an equal volume of assay buffer after capturing a baseline fluorescence in Ca<sup>2+</sup> signaling experiments.</p></sec><sec id="s4-7"><title>Patch clamping</title><p>Isolated chondrocytes were kept on ice and used for patching within 36 hr. Patch-clamp experiments were carried out at RT under two conditions. Single-channel measurements were made in excised inside-out membrane patches in a symmetric potassium chloride (KCl) solution (148 mM KCl, 1 mM K<sub>2</sub>EDTA, 1 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (egtazic acid; EGTA), 10 mM HEPES, pH 7.4). Channel activation was achieved by bath perfusion with the same buffer solution containing 10 nM GSK101. Blocking was performed using the same buffer solution supplied with both 10 nM GSK101 and 20 µM GSK205. Recordings were made at −30 mV membrane. Whole-cell currents were recorded using an external sodium chloride (NaCl) solution (150 mM NaCl, 5 mM KCl, 1 mM EGTA, 10 mM glucose, 10 mM HEPES, and 10 µM free Ca<sup>2+</sup>) and KCl pipette solution as used for single-channel recordings. Inhibition of basal currents was performed by pre-incubation of the cells in external solution supplied with 20 µM GSK205 for 20 min before patching; the drug was also present in the bath at the same concentration during the experiment. Data were acquired at 3 kHz, low-pass filtered at 1 kHz with Axopatch 1D patch-clamp amplifier and digitized with Digidata 1320 digitizer (Molecular Devices, San Jose, CA). Data analysis was performed using the pClamp software suite (Molecular Devices, San Jose, CA). Pipettes with 2.0–4.0 MOhm resistance in symmetric 150 mM KCl buffer were pulled from Kimble Chase 2502 soda lime glass with a Sutter P-86 puller (Sutter Instruments, Novato, CA).</p></sec><sec id="s4-8"><title>Confocal imaging of Ca<sup>2+</sup> signaling</title><p>hiPSC-derived chondrocytes from digested pellets were plated in DMEM medium containing 10% FBS at 2.1 × 10<sup>4</sup> cells/cm<sup>2</sup> in 35-mm dishes for 6–8 hr to allow the cells to adhere without dedifferentiating. Cells were then rinsed and stained for 30 min with Fluo-4 AM (cat. num. F14201; Thermo Fisher Scientific, Waltham, MA), Fura Red AM (cat. num. F3021; Thermo Fisher Scientific, Waltham, MA), and sulfinpyrazone (cat. num. S9509-5G; Sigma-Aldrich, St. Louis, MO) with 20 mM GSK205 or 1000× DMSO (vehicle control). The dye solution was replaced with assay buffer before imaging cells on a confocal microscope (LSM 880; Zeiss, Oberkochen, Germany) at baseline for the first 100 frames (approximately 6 min). Then, an equal volume of a 2× solution of GSK101 or GSK101 and GSK205 was added, and imaging continued for an additional 300 frames (approximately 20 min). Fiji software (ImageJ, version 2.1.0) was used to locate cells and quantify the ratiometric fluorescence intensity (Intensity<sub>fluo-4</sub>/Intensity<sub>fura red</sub>). In brief, .czi files were imported into Fiji and the channels were split. After applying the median filter, the image calculator divided the green channel by the red. A Z-projection was performed based on the maximum fluorescence of the red channel (to ensure that all cells were identified even in groups were there was no increase in Ca<sup>2+</sup> signaling). A threshold and watershed binary were then applied, and measurements were set for a cell size of 100-infinity. Outlines were projected, and the mean fluorescence of each cell was measured over time. The average fluorescence was plotted for all the cells in the group over time. Area under the curve and time of response were calculated to quantify differences between groups. Cells were classified as responders if they had a fluorescence greater than the baseline mean plus 3 times the standard deviation in at least a quarter of the frames. Time of response was the time of the first frame in which the cell responded for at least two consecutive frames. The fluorescence was measured for all the cells in the frame of view as technical replicates for two experimental replicates.</p></sec><sec id="s4-9"><title>AFM measurement of neocartilage mechanical properties</title><p>Day-28 and -42 hiPSC-derived pellets were rinsed in phosphate-buffered saline (PBS) and snap frozen in optimal cutting temperature (cat. num. 4583; Sakura Finetek, Torrance, CA) medium and stored at −80 °C. Pellets were cryosectioned using cryofilm (type 2C(10); Section-Lab, Hiroshima, Japan) in multiple different regions of the pellet (i.e., zones). The 10 µm cryosection with cryofilm was fixed on a microscope slide using chitosan and stored at 4°C overnight. The next day, cryosections were mechanically loaded using an AFM (MFP-3D Bio, Asylum Research, Goleta, CA) as previously described (<xref ref-type="bibr" rid="bib98">Votava et al., 2019</xref>). Briefly, the samples were tested in PBS at 37°C to maintain hydration and mimic physiologic conditions, respectively. The sections were mechanically probed using a silicon cantilever with a spherical tip (5 μm diameter, <italic>k</italic> ~ 7.83 N/m, Novascan Technologies, Ames, IA). An area of 10 μm<sup>2</sup> with 0.5 μm intervals (400 indentations) was loaded to 300 nN with the loading rate of 10 μm/s. Multiple locations from different sites of each zone and pellet were loaded as replicates. The curves obtained from AFM were imported into a custom written MATLAB code to determine the mechanical properties of the pellets. Using contact point extrapolation, the contact point between the cantilever’s tip and the tissue was detected, and the elastic modulus was calculated using a modified Hertz model (<xref ref-type="bibr" rid="bib18">Darling et al., 2010</xref>; <xref ref-type="bibr" rid="bib17">Darling et al., 2006</xref>; <xref ref-type="bibr" rid="bib98">Votava et al., 2019</xref>; <xref ref-type="bibr" rid="bib104">Wilusz et al., 2013</xref>; <xref ref-type="bibr" rid="bib109">Zelenski et al., 2015</xref>). This code is available at: <ext-link ext-link-type="uri" xlink:href="https://github.com/guilak-lab/programs/tree/guilak-lab-TRPV4-paper">https://github.com/guilak-lab/programs/tree/guilak-lab-TRPV4-paper</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:edc5c3acc6f200ddd634a7f0b5c604533da3e34d;origin=https://github.com/guilak-lab/programs;visit=swh:1:snp:99144a14b69688f12391b555ad349c37f13b8f5b;anchor=swh:1:rev:465cfaeea5676c514c264785b5db626513baa0d1">swh:1:rev:465cfaeea5676c514c264785b5db626513baa0d1</ext-link>; <xref ref-type="bibr" rid="bib21">Dicks et al., 2022</xref>).</p></sec><sec id="s4-10"><title>Histology</title><p>Chondrogenic pellets at days 7, 14, 28, 42, and 56 (with and without BMP4) were fixed and dehydrated in sequential steps of increasing ethanol and xylene solutions until embedded in paraffin wax. Wax blocks were cut into 8 µm sections on microscope slides for histological and immunohistochemical analysis. Slides were rehydrated in ethanol and water and the nuclei were stained with Harris hematoxylin and sGAGs with Safranin-O. Antigen retrieval was performed on rehydrated slides followed by blocking, the addition of primary and secondary antibodies, and AEC development to label collagen proteins (COL1A1, COL2A1, COL6A1, and COL10A1) and Vector Hematoxylin QS counterstain (cat. num. H-3404, Vector Laboratories, Newark, CA).</p></sec><sec id="s4-11"><title>Biochemical analysis</title><p>Chondrogenic pellets at days 7, 14, 28, and 42 were washed with PBS and digested in papain overnight at 65°C. sGAG and dsDNA content were measured using the dimethylmethylene blue (DMMB; cat. num. 341088, Sigma-Aldrich, St. Louis, MO) and PicoGreen assays (Quant-iT PicoGreen dsDNA Assay Kit; cat. num. P7589; Thermo Fisher Scientific, Waltham, MA), respectively. sGAG content was normalized to dsDNA. Three to four independent experiments were performed with 3–4 technical replicates per group.</p></sec><sec id="s4-12"><title>Western blot</title><p>Day-56 pellets treated with TGFβ3, TGFβ3 + BMP4, or BMP4 were digested to single cells, as described above, and lysed in RIPA buffer (cat. num. 9806S; Cell Signaling Technology, Danvers, MA) with protease inhibitor (cat. num. 87786; Thermo Fisher Scientific, Waltham, MA). Protein concentration was then measured using the BCA Assay (Pierce). Twenty micrograms of protein for each well were separated on 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis gel with pre-stained molecular weight markers (cat. num. 161-0374; Bio-Rad, Hercules, CA) and transferred to a polyvinylidene fluoride (PVDF) membrane. The PVDF membrane blots were incubated overnight at 4°C with the primary antibodies, respectively: anti-COL10A1 (1:500; cat. num. PA5-97603; Thermo Fisher Scientific, Waltham, MA), anti-RUNX2 (1:2000; cat. num. 41-1400, Thermo Fisher Scientific), anti-MMP13 (1;2000; cat. num. MA5-14238; Thermo Fisher Scientific, Waltham, MA), anti-IHH (1:500; cat. num. MA5-37541; Thermo Fisher Scientific, Waltham, MA), anti-ALPL (1:3000; cat. num. MAB29092, R&amp;D systems), and anti-GAPDH (1:30000; cat. num. 60004-1-Ig; Proteintech, Rosemont, IL) as the loading control. TidyBlot-Reagent-HRP (1:1000; cat. num. 147711; Bio-Rad, Hercules, CA) and horse anti-mouse IgG secondary antibody (1:3000; cat. num. 7076; Cell Signaling, Danvers, MA) were used accordingly. Immunoblots were imaged using the iBright FL1000 Imaging System (Thermo Fisher Scientific, Waltham, MA). Using photoshop, the images were inverted, and the protein abundance of each band was quantified by multiplying the mean of signal intensity by the pixels of the individual band. The relative protein abundance was normalized to the GAPDH levels. The maximum value was arbitrarily set to 1.</p></sec><sec id="s4-13"><title>RNA isolation</title><p>Chondrogenic pellets at days 7, 14, 28, 42, and 56 were washed with PBS, lysed, snap frozen, and homogenized. RNA was isolated using the Total RNA Purification Plus Kit (cat. num. 48400; Norgen Biotek, Thorold, Canada) and used immediately for either RT-qPCR or RNA-seq.</p></sec><sec id="s4-14"><title>Gene expression with RT-qPCR</title><p>Isolated RNA was reverse transcribed into cDNA. The cDNA was used to run real-time, quantitative PCR using Fast SYBR Green Master Mix (cat. num. 4385610; Thermo Fisher Scientific, Waltham, MA). Gene expression was analyzed using the ΔΔ<italic>C</italic><sub>T</sub> method with hiPSC as the reference time point and <italic>TBP</italic> as the housekeeping gene (<xref ref-type="bibr" rid="bib53">Livak and Schmittgen, 2001</xref>). Three to four independent experiments were performed with 3–4 technical replicates per group. Primers can be found in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p></sec><sec id="s4-15"><title>Genome-wide mRNA sequencing</title><p>Isolated RNA was treated with DNase (cat. num. 25720; Norgen Biotek, Thorold, Canada) and cleaned (cat. num. 43200; Norgen Biotek, Thorold, Canada) according to the manufacturer’s instructions prior to submitting to the Genome Technology Access Center at Washington University in St. Louis (GTAC). Libraries were prepared according to the manufacturer’s protocol. Samples were indexed, pooled, and sequenced at a depth of 30 million reads per sample on an Illumina NovaSeq 6000. Basecalls and demultiplexing were performed with Illumina’s bcl2fastq software and a custom python demultiplexing program with a maximum of one mismatch in the indexing read. RNA-seq reads were then aligned to the Ensembl release 76 primary assembly with STAR version 2.5.1a (<xref ref-type="bibr" rid="bib24">Dobin et al., 2013</xref>). Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.6-p5 (<xref ref-type="bibr" rid="bib52">Liao et al., 2014</xref>). Isoform expression of known Ensembl transcripts were estimated with Salmon version 0.8.2 (<xref ref-type="bibr" rid="bib79">Patro et al., 2017</xref>). Sequencing performance was assessed for the total number of aligned reads, total number of uniquely aligned reads, and features detected. The ribosomal fraction, known junction saturation, and read distribution over known gene models were quantified with RSeQC version 2.6.2 (<xref ref-type="bibr" rid="bib99">Wang et al., 2012</xref>).</p></sec><sec id="s4-16"><title>Transcriptomic analysis of sequencing datasets</title><p>R and the DESeq2 package were used to read un-normalized gene counts, and genes were removed if they had counts lower than 200 (<xref ref-type="bibr" rid="bib56">Love et al., 2014</xref>). Regularized-logarithm transformed data of the samples were visualized with the <italic>Pheatmap</italic> package (<xref ref-type="bibr" rid="bib43">Kolde, 2015</xref>) function on the calculated Euclidean distances between samples or with the <italic>ggplot2</italic> package (<xref ref-type="bibr" rid="bib102">Wickham, 2009</xref>) to create a PCA. The transformed data were also used to determine the top 5000 most variable genes across the samples. The replicates, from DESeq data, for each group were averaged together, and the up- and down-regulated DEGs were determined. The total number of DEGs was plotted using GraphPad Prism. At day 28, the V620I and T89I lines were compared to WT. At day 56, TGFβ3-treated V620I and T89I were compared to TGFβ3-treated WT, and BMP4-treated groups were compared to their respective TGFβ3-treated group of the same line (e.g., BMP4-treated WT vs. TGFβ3-treated WT). Genes were considered differentially expressed if adjusted p value (p<sub>adj</sub>) &lt;0.1 and log<sub>2</sub>(fold change) ≥1 or ≤−1. The intersecting and unique DEGs were determined and plotted with the <italic>intersect</italic> and <italic>setdiff</italic>, and <italic>venn.diagram</italic> functions (<italic>VennDiagram</italic> package; <xref ref-type="bibr" rid="bib13">Chen and Boutros, 2011</xref>). The fold changes of common chondrogenic, hypertrophic, growth factor, Ca<sup>2+</sup> signaling, and off-target genes, in the top 5000 most variable genes, were plotted using the <italic>pheatmap</italic> function. The top 25 most up- and down-regulated for each group, based on log<sub>2</sub>(fold change), and the log<sub>2</sub>(fold change) of that gene for the other group(s) were also plotted with the <italic>pheatmap</italic>. Gene lists (e.g., intersected genes, genes up-regulated with BMP4 treatment) were entered into g:profiler to determine associated GO Biological Processes, Molecular Functions, Cellular Components, KEGG pathways, Reactome pathways, and Human Phenotype (HP) Ontologies (<xref ref-type="bibr" rid="bib84">Raudvere et al., 2019</xref>). The negative log<sub>10</sub> of the adjusted p value for each term was plotted with GraphPad Prism or using a function to scale circle diameter to the p value in Illustrator.</p><p>The gap statistic method determined the ideal number of clusters resulting from BMP4 treatment was either 1 or 9. We then performed <italic>k</italic>-means clustering with 9 clusters and plotted the gene expression trends for each gene within the cluster with the average expression trend overlaying for each cell line of the largest cluster using the <italic>tidyverse</italic> package (<xref ref-type="bibr" rid="bib3">Altman and Krzywinski, 2017</xref>). The genes in each cluster, with the normalized counts for each group, are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. The largest cluster was plotted using the Cytoscape String app’s protein interaction to create a protein–protein network (<xref ref-type="bibr" rid="bib25">Doncheva et al., 2019</xref>; <xref ref-type="bibr" rid="bib89">Shannon et al., 2003</xref>). Using the average log fold change with BMP4 treatment across lines, the network was propagated using the Diffusion app, and functional enrichment with EnrichmentMap was performed on the network (<xref ref-type="bibr" rid="bib61">Merico et al., 2010</xref>). We then created a network connecting the genes to their associated genes with black lines and to their associated GO processes using gray lines. We colored the gene circles with three colors representing the log fold change of that gene in each line. The white arrows were added to the color scale legend to indicate maximum log fold change for each line.</p></sec><sec id="s4-17"><title>Statistical analysis</title><p>Data were graphed and analyzed using GraphPad Prism (Version 9.1.0). Outliers were removed from the data using the ROUT method (<italic>Q</italic> = 1%), and the data were tested for normality with the Shapiro–Wilk test (<italic>a</italic> = 0.05). For RT-qPCR, normally distributed data were analyzed within each time point using a Brown–Forsythe and Welch one-way analysis of variance (ANOVA) with multiple comparisons (mean of each column, cell line, with every other column). A Kruskal–Wallis test was used if data were not normally distributed. For biochemical analysis, mechanical properties, and area under the curve, and time of response, data were analyzed using an ordinary two-way ANOVA, comparing each cell with all other cells, with Tukey’s post hoc test. Area under the curve was quantified for plots over time considering a baseline of <italic>Y</italic> = 0, ignoring peaks less than 10% of the distance from minimum to maximum <italic>Y</italic>, and all peaks going over the baseline.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>Patents on TRPV4 inhibitors have been licensed to TRPblue (US Patents 9,701,675; 10,329,265; and 11,014,896). Dr. Liedtke is an executive employee of Regeneron Pharmaceuticals (Tarrytown NY).</p></fn><fn fn-type="COI-statement" id="conf4"><p>Patents on TRPV4 inhibitors licensed to TRPblue Inc (US Patents 9,701,675; 10,329,265; and 11,014,896)</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Additional figures to support data in <xref ref-type="fig" rid="fig2">Figures 2</xref>, <xref ref-type="fig" rid="fig3">3</xref> and <xref ref-type="fig" rid="fig5">5</xref>.</title><p><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>. Matrix production and mechanical properties through day 42 of chondrogenic differentiation. <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>. Gene expression using RT-qPCR through day 42 of chondrogenic differentiation. <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>. Top 15 mutant-specific differentially expressed genes (DEGs) compared to wildtype (WT) and genes of interest at days 28 and 56 as identified by RNA sequencing. <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>. Top 25 most up- and down-regulated DEGs compared to WT at day 56 as identified by RNA sequencing. <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>. Hypertrophic gene and protein expression in TGFβ3- and BMP4-treated day-56 chondrogenic pellets.</p></caption><media xlink:href="elife-71154-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-71154-transrepform1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All RNAseq data files generated and reported in this study are available on GEO (accession number GSE225446,<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225446">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225446</ext-link>).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Dicks</surname><given-names>AR</given-names></name><name><surname>Maksaev</surname><given-names>GI</given-names></name><name><surname>Harissa</surname><given-names>Z</given-names></name><name><surname>Savadipour</surname><given-names>A</given-names></name><name><surname>Tang</surname><given-names>R</given-names></name><name><surname>Steward</surname><given-names>N</given-names></name><name><surname>Liedtke</surname><given-names>W</given-names></name><name><surname>Nichols</surname><given-names>CG</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Skeletal dysplasia-causing TRPV4 mutations suppress the hypertrophic differentiation of human iPSC-derived chondrocytes</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225446">GSE225446</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by Shriners Hospitals for Children – St. Louis, the National Institutes of Health (R01 AG46927, R01 AG15768, R01 AR072999, R00 AR075899, P30 AR073752, P30 AR074992, T32 DK108742, T32 EB018266, and CTSA grant UL1 TR002345). We would like to thank the Washington University Genome Engineering and iPSC Center and the Genome Technology Access Center (GTAC) for their assistance with the CRISPR-Cas9 editing and RNA sequencing, respectively. We would also like to thank Dr. Monica Sala-Rabanal for assistance and advice in the initial aspects of this study.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adkar</surname><given-names>SS</given-names></name><name><surname>Brunger</surname><given-names>JM</given-names></name><name><surname>Willard</surname><given-names>VP</given-names></name><name><surname>Wu</surname><given-names>CL</given-names></name><name><surname>Gersbach</surname><given-names>CA</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome engineering for personalized arthritis therapeutics</article-title><source>Trends in Molecular Medicine</source><volume>23</volume><fpage>917</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2017.08.002</pub-id><pub-id pub-id-type="pmid">28887050</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adkar</surname><given-names>SS</given-names></name><name><surname>Wu</surname><given-names>CL</given-names></name><name><surname>Willard</surname><given-names>VP</given-names></name><name><surname>Dicks</surname><given-names>A</given-names></name><name><surname>Ettyreddy</surname><given-names>A</given-names></name><name><surname>Steward</surname><given-names>N</given-names></name><name><surname>Bhutani</surname><given-names>N</given-names></name><name><surname>Gersbach</surname><given-names>CA</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Step-wise chondrogenesis of human induced pluripotent stem cells and purification via a reporter allele generated by CRISPR-cas9 genome editing</article-title><source>Stem Cells</source><volume>37</volume><fpage>65</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1002/stem.2931</pub-id><pub-id pub-id-type="pmid">30378731</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>N</given-names></name><name><surname>Krzywinski</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Clustering</article-title><source>Nature Methods</source><volume>14</volume><fpage>545</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4299</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amano</surname><given-names>K</given-names></name><name><surname>Hata</surname><given-names>K</given-names></name><name><surname>Sugita</surname><given-names>A</given-names></name><name><surname>Takigawa</surname><given-names>Y</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Wakabayashi</surname><given-names>M</given-names></name><name><surname>Kogo</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>R</given-names></name><name><surname>Yoneda</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Sox9 family members negatively regulate maturation and calcification of chondrocytes through up-regulation of parathyroid hormone-related protein</article-title><source>Molecular Biology of the Cell</source><volume>20</volume><fpage>4541</fpage><lpage>4551</lpage><pub-id pub-id-type="doi">10.1091/mbc.e09-03-0227</pub-id><pub-id pub-id-type="pmid">19759178</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreucci</surname><given-names>E</given-names></name><name><surname>Aftimos</surname><given-names>S</given-names></name><name><surname>Alcausin</surname><given-names>M</given-names></name><name><surname>Haan</surname><given-names>E</given-names></name><name><surname>Hunter</surname><given-names>W</given-names></name><name><surname>Kannu</surname><given-names>P</given-names></name><name><surname>Kerr</surname><given-names>B</given-names></name><name><surname>McGillivray</surname><given-names>G</given-names></name><name><surname>McKinlay Gardner</surname><given-names>RJ</given-names></name><name><surname>Patricelli</surname><given-names>MG</given-names></name><name><surname>Sillence</surname><given-names>D</given-names></name><name><surname>Thompson</surname><given-names>E</given-names></name><name><surname>Zacharin</surname><given-names>M</given-names></name><name><surname>Zankl</surname><given-names>A</given-names></name><name><surname>Lamandé</surname><given-names>SR</given-names></name><name><surname>Savarirayan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Trpv4 related skeletal dysplasias: a phenotypic spectrum highlighted byclinical, radiographic, and molecular studies in 21 new families</article-title><source>Orphanet Journal of Rare Diseases</source><volume>6</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1186/1750-1172-6-37</pub-id><pub-id pub-id-type="pmid">21658220</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atashi</surname><given-names>F</given-names></name><name><surname>Modarressi</surname><given-names>A</given-names></name><name><surname>Pepper</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The role of reactive oxygen species in mesenchymal stem cell adipogenic and osteogenic differentiation: a review</article-title><source>Stem Cells and Development</source><volume>24</volume><fpage>1150</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1089/scd.2014.0484</pub-id><pub-id pub-id-type="pmid">25603196</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Breeland</surname><given-names>G</given-names></name><name><surname>Sinkler</surname><given-names>MA</given-names></name><name><surname>Menezes</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2021">2021</year><chapter-title>Embryology, bone ossification</chapter-title><source>SttatPearls</source><publisher-loc>Treasure Island, FL</publisher-loc><publisher-name>StatPearls Publishing</publisher-name><pub-id pub-id-type="pmid">35261461</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camacho</surname><given-names>N</given-names></name><name><surname>Krakow</surname><given-names>D</given-names></name><name><surname>Johnykutty</surname><given-names>S</given-names></name><name><surname>Katzman</surname><given-names>PJ</given-names></name><name><surname>Pepkowitz</surname><given-names>S</given-names></name><name><surname>Vriens</surname><given-names>J</given-names></name><name><surname>Nilius</surname><given-names>B</given-names></name><name><surname>Boyce</surname><given-names>BF</given-names></name><name><surname>Cohn</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Dominant TRPV4 mutations in nonlethal and lethal metatropic dysplasia</article-title><source>American Journal of Medical Genetics. Part A</source><volume>152A</volume><fpage>1169</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.33392</pub-id><pub-id pub-id-type="pmid">20425821</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Anishkin</surname><given-names>A</given-names></name><name><surname>Zinkevich</surname><given-names>NS</given-names></name><name><surname>Nishijima</surname><given-names>Y</given-names></name><name><surname>Korishettar</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Wilcox</surname><given-names>DA</given-names></name><name><surname>Zhang</surname><given-names>DX</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Transient receptor potential vanilloid 4 (TRPV4) activation by arachidonic acid requires protein kinase A-mediated phosphorylation</article-title><source>The Journal of Biological Chemistry</source><volume>293</volume><fpage>5307</fpage><lpage>5322</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.811075</pub-id><pub-id pub-id-type="pmid">29462784</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caron</surname><given-names>MMJ</given-names></name><name><surname>Janssen</surname><given-names>MPF</given-names></name><name><surname>Peeters</surname><given-names>L</given-names></name><name><surname>Haudenschild</surname><given-names>DR</given-names></name><name><surname>Cremers</surname><given-names>A</given-names></name><name><surname>Surtel</surname><given-names>DAM</given-names></name><name><surname>van Rhijn</surname><given-names>LW</given-names></name><name><surname>Emans</surname><given-names>PJ</given-names></name><name><surname>Welting</surname><given-names>TJM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Aggrecan and COMP improve periosteal chondrogenesis by delaying chondrocyte hypertrophic maturation</article-title><source>Frontiers in Bioengineering and Biotechnology</source><volume>8</volume><elocation-id>1036</elocation-id><pub-id pub-id-type="doi">10.3389/fbioe.2020.01036</pub-id><pub-id pub-id-type="pmid">32984292</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Greer</surname><given-names>J</given-names></name><name><surname>Capecchi</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Analysis of hoxa7/hoxb7 mutants suggests periodicity in the generation of the different sets of vertebrae</article-title><source>Mechanisms of Development</source><volume>77</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/s0925-4773(98)00126-9</pub-id><pub-id pub-id-type="pmid">9784603</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CT</given-names></name><name><surname>Shih</surname><given-names>YRV</given-names></name><name><surname>Kuo</surname><given-names>TK</given-names></name><name><surname>Lee</surname><given-names>OK</given-names></name><name><surname>Wei</surname><given-names>YH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells</article-title><source>Stem Cells</source><volume>26</volume><fpage>960</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1634/stemcells.2007-0509</pub-id><pub-id pub-id-type="pmid">18218821</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Boutros</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>VennDiagram: a package for the generation of highly-customizable venn and euler diagrams in R</article-title><source>BMC Bioinformatics</source><volume>12</volume><elocation-id>35</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-35</pub-id><pub-id pub-id-type="pmid">21269502</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>WC</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Sng</surname><given-names>TJ</given-names></name><name><surname>Ong</surname><given-names>YJ</given-names></name><name><surname>Tan</surname><given-names>W-L</given-names></name><name><surname>Ang</surname><given-names>VY</given-names></name><name><surname>Foldager</surname><given-names>CB</given-names></name><name><surname>Toh</surname><given-names>WS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Distribution of pericellular matrix molecules in the temporomandibular joint and their chondroprotective effects against inflammation</article-title><source>International Journal of Oral Science</source><volume>9</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/ijos.2016.57</pub-id><pub-id pub-id-type="pmid">28282029</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craft</surname><given-names>AM</given-names></name><name><surname>Rockel</surname><given-names>JS</given-names></name><name><surname>Nartiss</surname><given-names>Y</given-names></name><name><surname>Kandel</surname><given-names>RA</given-names></name><name><surname>Alman</surname><given-names>BA</given-names></name><name><surname>Keller</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Generation of articular chondrocytes from human pluripotent stem cells</article-title><source>Nature Biotechnology</source><volume>33</volume><fpage>638</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1038/nbt.3210</pub-id><pub-id pub-id-type="pmid">25961409</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creuzet</surname><given-names>S</given-names></name><name><surname>Couly</surname><given-names>G</given-names></name><name><surname>Vincent</surname><given-names>C</given-names></name><name><surname>Le Douarin</surname><given-names>NM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Negative effect of hox gene expression on the development of the neural crest-derived facial skeleton</article-title><source>Development</source><volume>129</volume><fpage>4301</fpage><lpage>4313</lpage><pub-id pub-id-type="doi">10.1242/dev.129.18.4301</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darling</surname><given-names>EM</given-names></name><name><surname>Zauscher</surname><given-names>S</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Viscoelastic properties of zonal articular chondrocytes measured by atomic force microscopy</article-title><source>Osteoarthritis and Cartilage</source><volume>14</volume><fpage>571</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2005.12.003</pub-id><pub-id pub-id-type="pmid">16478668</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darling</surname><given-names>EM</given-names></name><name><surname>Wilusz</surname><given-names>RE</given-names></name><name><surname>Bolognesi</surname><given-names>MP</given-names></name><name><surname>Zauscher</surname><given-names>S</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Spatial mapping of the biomechanical properties of the pericellular matrix of articular cartilage measured in situ via atomic force microscopy</article-title><source>Biophysical Journal</source><volume>98</volume><fpage>2848</fpage><lpage>2856</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2010.03.037</pub-id><pub-id pub-id-type="pmid">20550897</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deprez</surname><given-names>PML</given-names></name><name><surname>Nichane</surname><given-names>MG</given-names></name><name><surname>Lengelé</surname><given-names>BG</given-names></name><name><surname>Rezsöhazy</surname><given-names>R</given-names></name><name><surname>Nyssen-Behets</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular study of a hoxa2 gain-of-function in chondrogenesis: a model of idiopathic proportionate short stature</article-title><source>International Journal of Molecular Sciences</source><volume>14</volume><fpage>20386</fpage><lpage>20398</lpage><pub-id pub-id-type="doi">10.3390/ijms141020386</pub-id><pub-id pub-id-type="pmid">24129174</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dicks</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>CL</given-names></name><name><surname>Steward</surname><given-names>N</given-names></name><name><surname>Adkar</surname><given-names>SS</given-names></name><name><surname>Gersbach</surname><given-names>CA</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Prospective isolation of chondroprogenitors from human ipscs based on cell surface markers identified using a CRISPR-cas9-generated reporter</article-title><source>Stem Cell Research &amp; Therapy</source><volume>11</volume><elocation-id>66</elocation-id><pub-id pub-id-type="doi">10.1186/s13287-020-01597-8</pub-id><pub-id pub-id-type="pmid">32070421</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Dicks</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>CL</given-names></name><name><surname>Savadipour</surname><given-names>A</given-names></name><name><surname>Votava</surname><given-names>L</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>AFM_Stiffness_Data_Program.m</data-title><source>In Github</source><ext-link ext-link-type="uri" xlink:href="https://github.com/guilak-lab/programs/tree/guilak-lab-TRPV4-paper">https://github.com/guilak-lab/programs/tree/guilak-lab-TRPV4-paper</ext-link></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diekman</surname><given-names>BO</given-names></name><name><surname>Christoforou</surname><given-names>N</given-names></name><name><surname>Willard</surname><given-names>VP</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Sanchez-Adams</surname><given-names>J</given-names></name><name><surname>Leong</surname><given-names>KW</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cartilage tissue engineering using differentiated and purified induced pluripotent stem cells</article-title><source>PNAS</source><volume>109</volume><fpage>19172</fpage><lpage>19177</lpage><pub-id pub-id-type="doi">10.1073/pnas.1210422109</pub-id><pub-id pub-id-type="pmid">23115336</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dix</surname><given-names>A</given-names></name><name><surname>Czakai</surname><given-names>K</given-names></name><name><surname>Springer</surname><given-names>J</given-names></name><name><surname>Fliesser</surname><given-names>M</given-names></name><name><surname>Bonin</surname><given-names>M</given-names></name><name><surname>Guthke</surname><given-names>R</given-names></name><name><surname>Schmitt</surname><given-names>AL</given-names></name><name><surname>Einsele</surname><given-names>H</given-names></name><name><surname>Linde</surname><given-names>J</given-names></name><name><surname>Löffler</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genome-wide expression profiling reveals S100B as biomarker for invasive aspergillosis</article-title><source>Frontiers in Microbiology</source><volume>7</volume><elocation-id>320</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2016.00320</pub-id><pub-id pub-id-type="pmid">27047454</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Star: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doncheva</surname><given-names>NT</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Gorodkin</surname><given-names>J</given-names></name><name><surname>Jensen</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cytoscape stringapp: network analysis and visualization of proteomics data</article-title><source>Journal of Proteome Research</source><volume>18</volume><fpage>623</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.8b00702</pub-id><pub-id pub-id-type="pmid">30450911</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fragonas</surname><given-names>E</given-names></name><name><surname>Pollesello</surname><given-names>P</given-names></name><name><surname>Mlinárik</surname><given-names>V</given-names></name><name><surname>Toffanin</surname><given-names>R</given-names></name><name><surname>Grando</surname><given-names>C</given-names></name><name><surname>Godeas</surname><given-names>C</given-names></name><name><surname>Vittur</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Sensitivity of chondrocytes of growing cartilage to reactive oxygen species</article-title><source>Biochimica et Biophysica Acta</source><volume>1425</volume><fpage>103</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/s0304-4165(98)00055-5</pub-id><pub-id pub-id-type="pmid">9813264</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Liesveld</surname><given-names>J</given-names></name><name><surname>Anolik</surname><given-names>J</given-names></name><name><surname>Mcdavid</surname><given-names>A</given-names></name><name><surname>Looney</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Ifnβ signaling inhibits osteogenesis in human SLE bone marrow</article-title><source>Lupus</source><volume>29</volume><fpage>1040</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1177/0961203320930088</pub-id><pub-id pub-id-type="pmid">32515653</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanagata</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Morita</surname><given-names>H</given-names></name><name><surname>Takemura</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Minowa</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Characterization of the osteoblast-specific transmembrane protein IFITM5 and analysis of IFITM5-deficient mice</article-title><source>Journal of Bone and Mineral Metabolism</source><volume>29</volume><fpage>279</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1007/s00774-010-0221-0</pub-id><pub-id pub-id-type="pmid">20838829</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanagata</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>IFITM5 mutations and osteogenesis imperfecta</article-title><source>Journal of Bone and Mineral Metabolism</source><volume>34</volume><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1007/s00774-015-0667-1</pub-id><pub-id pub-id-type="pmid">26031935</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>T</given-names></name><name><surname>Müller</surname><given-names>C</given-names></name><name><surname>Gebhard</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>E</given-names></name><name><surname>Pausch</surname><given-names>F</given-names></name><name><surname>Schlund</surname><given-names>B</given-names></name><name><surname>Bösl</surname><given-names>MR</given-names></name><name><surname>Hess</surname><given-names>A</given-names></name><name><surname>Surmann-Schmitt</surname><given-names>C</given-names></name><name><surname>von der Mark</surname><given-names>H</given-names></name><name><surname>de Crombrugghe</surname><given-names>B</given-names></name><name><surname>von der Mark</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sox9 is a major negative regulator of cartilage vascularization, bone marrow formation and endochondral ossification</article-title><source>Development</source><volume>137</volume><fpage>901</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1242/dev.045203</pub-id><pub-id pub-id-type="pmid">20179096</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>JD</given-names></name><name><surname>Flanagan</surname><given-names>JU</given-names></name><name><surname>Jowsey</surname><given-names>IR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Glutathione transferases</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>45</volume><fpage>51</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.45.120403.095857</pub-id><pub-id pub-id-type="pmid">15822171</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hecht</surname><given-names>JT</given-names></name><name><surname>Sage</surname><given-names>EH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Retention of the matricellular protein SPARC in the endoplasmic reticulum of chondrocytes from patients with pseudoachondroplasia</article-title><source>The Journal of Histochemistry and Cytochemistry</source><volume>54</volume><fpage>269</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1369/jhc.5C6834.2005</pub-id><pub-id pub-id-type="pmid">16286662</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>W</given-names></name><name><surname>Fu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Duan</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Weng</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cation channel transient receptor potential vanilloid 4 mediates topography-induced osteoblastic differentiation of bone marrow stem cells</article-title><source>ACS Biomaterials Science &amp; Engineering</source><volume>5</volume><fpage>6520</fpage><lpage>6529</lpage><pub-id pub-id-type="doi">10.1021/acsbiomaterials.9b01237</pub-id><pub-id pub-id-type="pmid">33417804</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Ho</surname><given-names>HH</given-names></name><name><surname>Lou</surname><given-names>O</given-names></name><name><surname>Hidaka</surname><given-names>C</given-names></name><name><surname>Ivashkiv</surname><given-names>LB</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Homeostatic role of interferons conferred by inhibition of IL-1-mediated inflammation and tissue destruction</article-title><source>Journal of Immunology</source><volume>175</volume><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.1.131</pub-id><pub-id pub-id-type="pmid">15972639</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Hendriks</surname><given-names>J</given-names></name><name><surname>Post</surname><given-names>JN</given-names></name><name><surname>Karperien</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The effects of the Wnt-signaling modulators BIO and PKF118-310 on the chondrogenic differentiation of human mesenchymal stem cells</article-title><source>International Journal of Molecular Sciences</source><volume>19</volume><elocation-id>561</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19020561</pub-id><pub-id pub-id-type="pmid">29438298</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huynh</surname><given-names>NPT</given-names></name><name><surname>Gloss</surname><given-names>CC</given-names></name><name><surname>Lorentz</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>R</given-names></name><name><surname>Brunger</surname><given-names>JM</given-names></name><name><surname>McAlinden</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Long non-coding RNA <italic>graslnd</italic> enhances chondrogenesis via suppression of the interferon type II signaling pathway</article-title><source>eLife</source><volume>9</volume><elocation-id>e49558</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.49558</pub-id><pub-id pub-id-type="pmid">32202492</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iimura</surname><given-names>T</given-names></name><name><surname>Pourquié</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Hox genes in time and space during vertebrate body formation</article-title><source>Development, Growth &amp; Differentiation</source><volume>49</volume><fpage>265</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1111/j.1440-169X.2007.00928.x</pub-id><pub-id pub-id-type="pmid">17501904</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Jaimes</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>D</given-names></name><name><surname>Walters</surname><given-names>ET</given-names></name><name><surname>O’Neil</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Determinants of TRPV4 activity following selective activation by small molecule agonist GSK1016790A</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e16713</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0016713</pub-id><pub-id pub-id-type="pmid">21339821</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2012">2012</year><chapter-title>The mutation of transient receptor potential vanilloid 4 (TRPV4) cation channel in human diseases</chapter-title><person-group person-group-type="editor"><name><surname>Rajnikant</surname><given-names>Mishra</given-names></name></person-group><source>Mutagenesis</source><publisher-name>InTechOpen</publisher-name><pub-id pub-id-type="doi">10.5772/50520</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SS</given-names></name><name><surname>Shin</surname><given-names>SH</given-names></name><name><surname>Auh</surname><given-names>CK</given-names></name><name><surname>Chun</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Human skeletal dysplasia caused by a constitutive activated transient receptor potential vanilloid 4 (TRPV4) cation channel mutation</article-title><source>Experimental &amp; Molecular Medicine</source><volume>44</volume><fpage>707</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.3858/emm.2012.44.12.080</pub-id><pub-id pub-id-type="pmid">23143559</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanju</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Yeo</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Romac</surname><given-names>J</given-names></name><name><surname>Shahid</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>P</given-names></name><name><surname>Gooden</surname><given-names>DM</given-names></name><name><surname>Simon</surname><given-names>SA</given-names></name><name><surname>Spasojevic</surname><given-names>I</given-names></name><name><surname>Mook</surname><given-names>RA</given-names></name><name><surname>Liddle</surname><given-names>RA</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name><name><surname>Liedtke</surname><given-names>WB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Small molecule dual-inhibitors of TRPV4 and TRPA1 for attenuation of inflammation and pain</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>26894</elocation-id><pub-id pub-id-type="doi">10.1038/srep26894</pub-id><pub-id pub-id-type="pmid">27247148</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanzler</surname><given-names>B</given-names></name><name><surname>Kuschert</surname><given-names>SJ</given-names></name><name><surname>Liu</surname><given-names>YH</given-names></name><name><surname>Mallo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Hoxa-2 restricts the chondrogenic domain and inhibits bone formation during development of the branchial area</article-title><source>Development</source><volume>125</volume><fpage>2587</fpage><lpage>2597</lpage><pub-id pub-id-type="doi">10.1242/dev.125.14.2587</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Kolde</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><data-title>Pheatmap: pretty heatmaps</data-title><source>Pheatmap</source><ext-link ext-link-type="uri" xlink:href="https://rdrr.io/cran/pheatmap/">https://rdrr.io/cran/pheatmap/</ext-link></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komori</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Runx2, an inducer of osteoblast and chondrocyte differentiation</article-title><source>Histochemistry and Cell Biology</source><volume>149</volume><fpage>313</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1007/s00418-018-1640-6</pub-id><pub-id pub-id-type="pmid">29356961</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krakow</surname><given-names>D</given-names></name><name><surname>Rimoin</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The skeletal dysplasias</article-title><source>Genetics in Medicine</source><volume>12</volume><fpage>327</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1097/GIM.0b013e3181daae9b</pub-id><pub-id pub-id-type="pmid">20556869</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leddy</surname><given-names>HA</given-names></name><name><surname>McNulty</surname><given-names>AL</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name><name><surname>Liedtke</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014a</year><article-title>Unraveling the mechanism by which TRPV4 mutations cause skeletal dysplasias</article-title><source>Rare Diseases</source><volume>2</volume><elocation-id>e962971</elocation-id><pub-id pub-id-type="doi">10.4161/2167549X.2014.962971</pub-id><pub-id pub-id-type="pmid">26942100</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leddy</surname><given-names>HA</given-names></name><name><surname>McNulty</surname><given-names>AL</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Rothfusz</surname><given-names>NE</given-names></name><name><surname>Gloss</surname><given-names>B</given-names></name><name><surname>Kirby</surname><given-names>ML</given-names></name><name><surname>Hutson</surname><given-names>MR</given-names></name><name><surname>Cohn</surname><given-names>DH</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name><name><surname>Liedtke</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014b</year><article-title>Follistatin in chondrocytes: the link between TRPV4 channelopathies and skeletal malformations</article-title><source>FASEB Journal</source><volume>28</volume><fpage>2525</fpage><lpage>2537</lpage><pub-id pub-id-type="doi">10.1096/fj.13-245936</pub-id><pub-id pub-id-type="pmid">24577120</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M-S</given-names></name><name><surname>Stebbins</surname><given-names>MJ</given-names></name><name><surname>Jiao</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>H-C</given-names></name><name><surname>Leiferman</surname><given-names>EM</given-names></name><name><surname>Walczak</surname><given-names>BE</given-names></name><name><surname>Palecek</surname><given-names>SP</given-names></name><name><surname>Shusta</surname><given-names>EV</given-names></name><name><surname>Li</surname><given-names>W-J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Comparative evaluation of isogenic mesodermal and ectomesodermal chondrocytes from human ipscs for cartilage regeneration</article-title><source>Science Advances</source><volume>7</volume><elocation-id>eabf0907</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abf0907</pub-id><pub-id pub-id-type="pmid">34138734</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leijten</surname><given-names>JCH</given-names></name><name><surname>Moreira Teixeira</surname><given-names>LS</given-names></name><name><surname>Landman</surname><given-names>EBM</given-names></name><name><surname>van Blitterswijk</surname><given-names>CA</given-names></name><name><surname>Karperien</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hypoxia inhibits hypertrophic differentiation and endochondral ossification in explanted tibiae</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e49896</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0049896</pub-id><pub-id pub-id-type="pmid">23185479</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Bmp signaling and hox transcription factors in limb development</article-title><source>Frontiers in Bioscience</source><volume>8</volume><fpage>s805</fpage><lpage>s812</lpage><pub-id pub-id-type="doi">10.2741/1150</pub-id><pub-id pub-id-type="pmid">12957873</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Bmp signaling and skeletogenesis</article-title><source>Annals of the New York Academy of Sciences</source><volume>1068</volume><fpage>26</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1196/annals.1346.006</pub-id><pub-id pub-id-type="pmid">16831903</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-delta delta C (T)) method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>KM</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Koh</surname><given-names>PW</given-names></name><name><surname>Deng</surname><given-names>TZ</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Tsai</surname><given-names>JM</given-names></name><name><surname>Barkal</surname><given-names>AA</given-names></name><name><surname>Shen</surname><given-names>KY</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Morganti</surname><given-names>RM</given-names></name><name><surname>Shyh-Chang</surname><given-names>N</given-names></name><name><surname>Fernhoff</surname><given-names>NB</given-names></name><name><surname>George</surname><given-names>BM</given-names></name><name><surname>Wernig</surname><given-names>G</given-names></name><name><surname>Salomon</surname><given-names>REA</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Vogel</surname><given-names>H</given-names></name><name><surname>Epstein</surname><given-names>JA</given-names></name><name><surname>Kundaje</surname><given-names>A</given-names></name><name><surname>Talbot</surname><given-names>WS</given-names></name><name><surname>Beachy</surname><given-names>PA</given-names></name><name><surname>Ang</surname><given-names>LT</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mapping the pairwise choices leading from pluripotency to human bone, heart, and other mesoderm cell types</article-title><source>Cell</source><volume>166</volume><fpage>451</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.06.011</pub-id><pub-id pub-id-type="pmid">27419872</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loukin</surname><given-names>S</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Kung</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Increased basal activity is a key determinant in the severity of human skeletal dysplasia caused by TRPV4 mutations</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e19533</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0019533</pub-id><pub-id pub-id-type="pmid">21573172</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with deseq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Miclau</surname><given-names>T</given-names></name><name><surname>Helms</surname><given-names>JA</given-names></name><name><surname>Colnot</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mepe is expressed during skeletal development and regeneration</article-title><source>Histochemistry and Cell Biology</source><volume>121</volume><fpage>493</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1007/s00418-004-0653-5</pub-id><pub-id pub-id-type="pmid">15221418</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lui</surname><given-names>JC</given-names></name><name><surname>Yue</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Kikani</surname><given-names>B</given-names></name><name><surname>Temnycky</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>KM</given-names></name><name><surname>Baron</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Persistent sox9 expression in hypertrophic chondrocytes suppresses transdifferentiation into osteoblasts</article-title><source>Bone</source><volume>125</volume><fpage>169</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2019.05.027</pub-id><pub-id pub-id-type="pmid">31121357</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Mack</surname><given-names>MR</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Qian</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>O’Neil</surname><given-names>RG</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Carlton</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>BS</given-names></name><name><surname>Renner</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Transient receptor potential vanilloid 4-expressing macrophages and keratinocytes contribute differentially to allergic and nonallergic chronic itch</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>141</volume><fpage>608</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2017.05.051</pub-id><pub-id pub-id-type="pmid">28807414</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massip</surname><given-names>L</given-names></name><name><surname>Ectors</surname><given-names>F</given-names></name><name><surname>Deprez</surname><given-names>P</given-names></name><name><surname>Maleki</surname><given-names>M</given-names></name><name><surname>Behets</surname><given-names>C</given-names></name><name><surname>Lengelé</surname><given-names>B</given-names></name><name><surname>Delahaut</surname><given-names>P</given-names></name><name><surname>Picard</surname><given-names>J</given-names></name><name><surname>Rezsöhazy</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Expression of hoxa2 in cells entering chondrogenesis impairs overall cartilage development</article-title><source>Differentiation; Research in Biological Diversity</source><volume>75</volume><fpage>256</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1111/j.1432-0436.2006.00132.x</pub-id><pub-id pub-id-type="pmid">17359301</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merico</surname><given-names>D</given-names></name><name><surname>Isserlin</surname><given-names>R</given-names></name><name><surname>Stueker</surname><given-names>O</given-names></name><name><surname>Emili</surname><given-names>A</given-names></name><name><surname>Bader</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Enrichment map: a network-based method for gene-set enrichment visualization and interpretation</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e13984</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0013984</pub-id><pub-id pub-id-type="pmid">21085593</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michigami</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Current understanding on the molecular basis of chondrogenesis</article-title><source>Clinical Pediatric Endocrinology</source><volume>23</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1292/cpe.23.1</pub-id><pub-id pub-id-type="pmid">24532955</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millán</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The role of phosphatases in the initiation of skeletal mineralization</article-title><source>Calcified Tissue International</source><volume>93</volume><fpage>299</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1007/s00223-012-9672-8</pub-id><pub-id pub-id-type="pmid">23183786</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miraoui</surname><given-names>H</given-names></name><name><surname>Marie</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Pivotal role of twist in skeletal biology and pathology</article-title><source>Gene</source><volume>468</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2010.07.013</pub-id><pub-id pub-id-type="pmid">20696219</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moffatt</surname><given-names>P</given-names></name><name><surname>Gaumond</surname><given-names>M-H</given-names></name><name><surname>Salois</surname><given-names>P</given-names></name><name><surname>Sellin</surname><given-names>K</given-names></name><name><surname>Bessette</surname><given-names>M-C</given-names></name><name><surname>Godin</surname><given-names>E</given-names></name><name><surname>de Oliveira</surname><given-names>PT</given-names></name><name><surname>Atkins</surname><given-names>GJ</given-names></name><name><surname>Nanci</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Bril: a novel bone-specific modulator of mineralization</article-title><source>Journal of Bone and Mineral Research</source><volume>23</volume><fpage>1497</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1359/jbmr.080412</pub-id><pub-id pub-id-type="pmid">18442316</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>K</given-names></name><name><surname>Miyamoto</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>N</given-names></name><name><surname>Kubota</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Takubo</surname><given-names>K</given-names></name><name><surname>Miyamoto</surname><given-names>K</given-names></name><name><surname>Ninomiya</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Iwasaki</surname><given-names>R</given-names></name><name><surname>Yagi</surname><given-names>M</given-names></name><name><surname>Takaishi</surname><given-names>H</given-names></name><name><surname>Toyama</surname><given-names>Y</given-names></name><name><surname>Suda</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Reactive oxygen species induce chondrocyte hypertrophy in endochondral ossification</article-title><source>The Journal of Experimental Medicine</source><volume>204</volume><fpage>1613</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.1084/jem.20062525</pub-id><pub-id pub-id-type="pmid">17576777</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muramatsu</surname><given-names>S</given-names></name><name><surname>Wakabayashi</surname><given-names>M</given-names></name><name><surname>Ohno</surname><given-names>T</given-names></name><name><surname>Amano</surname><given-names>K</given-names></name><name><surname>Ooishi</surname><given-names>R</given-names></name><name><surname>Sugahara</surname><given-names>T</given-names></name><name><surname>Shiojiri</surname><given-names>S</given-names></name><name><surname>Tashiro</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Nishimura</surname><given-names>R</given-names></name><name><surname>Kuhara</surname><given-names>S</given-names></name><name><surname>Sugano</surname><given-names>S</given-names></name><name><surname>Yoneda</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Functional gene screening system identified TRPV4 as a regulator of chondrogenic differentiation</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>32158</fpage><lpage>32167</lpage><pub-id pub-id-type="doi">10.1074/jbc.M706158200</pub-id><pub-id pub-id-type="pmid">17804410</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemec</surname><given-names>SF</given-names></name><name><surname>Cohn</surname><given-names>DH</given-names></name><name><surname>Krakow</surname><given-names>D</given-names></name><name><surname>Funari</surname><given-names>VA</given-names></name><name><surname>Rimoin</surname><given-names>DL</given-names></name><name><surname>Lachman</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The importance of conventional radiography in the mutational analysis of skeletal dysplasias (the TRPV4 mutational family)</article-title><source>Pediatric Radiology</source><volume>42</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s00247-011-2229-6</pub-id><pub-id pub-id-type="pmid">21863289</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>A-V</given-names></name><name><surname>Thapa</surname><given-names>M</given-names></name><name><surname>Otjen</surname><given-names>J</given-names></name><name><surname>Kamps</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Skeletal dysplasias: radiologic approach with common and notable entities</article-title><source>Seminars in Musculoskeletal Radiology</source><volume>22</volume><fpage>66</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1055/s-0037-1608005</pub-id><pub-id pub-id-type="pmid">29409074</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nims</surname><given-names>RJ</given-names></name><name><surname>Pferdehirt</surname><given-names>L</given-names></name><name><surname>Ho</surname><given-names>NB</given-names></name><name><surname>Savadipour</surname><given-names>A</given-names></name><name><surname>Lorentz</surname><given-names>J</given-names></name><name><surname>Sohi</surname><given-names>S</given-names></name><name><surname>Kassab</surname><given-names>J</given-names></name><name><surname>Ross</surname><given-names>AK</given-names></name><name><surname>O’Conor</surname><given-names>CJ</given-names></name><name><surname>Liedtke</surname><given-names>WB</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>McNulty</surname><given-names>AL</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A synthetic mechanogenetic gene circuit for autonomous drug delivery in engineered tissues</article-title><source>Science Advances</source><volume>7</volume><elocation-id>eabd9858</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abd9858</pub-id><pub-id pub-id-type="pmid">33571125</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>R</given-names></name><name><surname>Hata</surname><given-names>K</given-names></name><name><surname>Matsubara</surname><given-names>T</given-names></name><name><surname>Wakabayashi</surname><given-names>M</given-names></name><name><surname>Yoneda</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012a</year><article-title>Regulation of bone and cartilage development by network between BMP signalling and transcription factors</article-title><source>Journal of Biochemistry</source><volume>151</volume><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1093/jb/mvs004</pub-id><pub-id pub-id-type="pmid">22253449</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>R</given-names></name><name><surname>Hata</surname><given-names>K</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Amano</surname><given-names>K</given-names></name><name><surname>Takigawa</surname><given-names>Y</given-names></name><name><surname>Wakabayashi</surname><given-names>M</given-names></name><name><surname>Takashima</surname><given-names>R</given-names></name><name><surname>Yoneda</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012b</year><article-title>Regulation of endochondral ossification by transcription factors</article-title><source>Frontiers in Bioscience</source><volume>17</volume><fpage>2657</fpage><lpage>2666</lpage><pub-id pub-id-type="doi">10.2741/4076</pub-id><pub-id pub-id-type="pmid">22652803</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonaka</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Yamaza</surname><given-names>H</given-names></name><name><surname>Hirofuji</surname><given-names>Y</given-names></name><name><surname>Masuda</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Novel gain-of-function mutation of <italic>trpv4</italic> associated with accelerated chondrogenic differentiation of dental pulp stem cells derived from a patient with metatropic dysplasia</article-title><source>Biochemistry and Biophysics Reports</source><volume>19</volume><elocation-id>100648</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbrep.2019.100648</pub-id><pub-id pub-id-type="pmid">31463371</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Conor</surname><given-names>CJ</given-names></name><name><surname>Leddy</surname><given-names>HA</given-names></name><name><surname>Benefield</surname><given-names>HC</given-names></name><name><surname>Liedtke</surname><given-names>WB</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TRPV4-mediated mechanotransduction regulates the metabolic response of chondrocytes to dynamic loading</article-title><source>PNAS</source><volume>111</volume><fpage>1316</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1073/pnas.1319569111</pub-id><pub-id pub-id-type="pmid">24474754</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohta</surname><given-names>N</given-names></name><name><surname>Ishiguro</surname><given-names>S</given-names></name><name><surname>Kawabata</surname><given-names>A</given-names></name><name><surname>Uppalapati</surname><given-names>D</given-names></name><name><surname>Pyle</surname><given-names>M</given-names></name><name><surname>Troyer</surname><given-names>D</given-names></name><name><surname>De</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Becker</surname><given-names>KG</given-names></name><name><surname>Tamura</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Human umbilical cord matrix mesenchymal stem cells suppress the growth of breast cancer by expression of tumor suppressor genes</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0123756</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0123756</pub-id><pub-id pub-id-type="pmid">25942583</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orioli</surname><given-names>IM</given-names></name><name><surname>Castilla</surname><given-names>EE</given-names></name><name><surname>Barbosa-Neto</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>The birth prevalence rates for the skeletal dysplasias</article-title><source>Journal of Medical Genetics</source><volume>23</volume><fpage>328</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1136/jmg.23.4.328</pub-id><pub-id pub-id-type="pmid">3746832</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>G</given-names></name><name><surname>Mezin</surname><given-names>F</given-names></name><name><surname>Juge-Aubry</surname><given-names>CE</given-names></name><name><surname>Plater-Zyberk</surname><given-names>C</given-names></name><name><surname>Gabay</surname><given-names>C</given-names></name><name><surname>Guerne</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Interferon beta stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts</article-title><source>Annals of the Rheumatic Diseases</source><volume>63</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1136/ard.2002.005546</pub-id><pub-id pub-id-type="pmid">14672890</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Z</given-names></name><name><surname>Gan</surname><given-names>W</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Hou</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MiR-1245a promotes the proliferation and invasion of colon adenocarcinoma by targeting BRCA2</article-title><source>Annals of Translational Medicine</source><volume>7</volume><elocation-id>777</elocation-id><pub-id pub-id-type="doi">10.21037/atm.2019.11.29</pub-id><pub-id pub-id-type="pmid">32042793</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patro</surname><given-names>R</given-names></name><name><surname>Duggal</surname><given-names>G</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Kingsford</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Salmon provides fast and bias-aware quantification of transcript expression</article-title><source>Nature Methods</source><volume>14</volume><fpage>417</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4197</pub-id><pub-id pub-id-type="pmid">28263959</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pineault</surname><given-names>KM</given-names></name><name><surname>Wellik</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hox genes and limb musculoskeletal development</article-title><source>Current Osteoporosis Reports</source><volume>12</volume><fpage>420</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1007/s11914-014-0241-0</pub-id><pub-id pub-id-type="pmid">25266923</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polur</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>PL</given-names></name><name><surname>Servais</surname><given-names>JM</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Role of HTRA1, a serine protease, in the progression of articular cartilage degeneration</article-title><source>Histology and Histopathology</source><volume>25</volume><fpage>599</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.14670/HH-25.599</pub-id><pub-id pub-id-type="pmid">20238298</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prein</surname><given-names>C</given-names></name><name><surname>Beier</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>ECM signaling in cartilage development and endochondral ossification</article-title><source>Current Topics in Developmental Biology</source><volume>133</volume><fpage>25</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/bs.ctdb.2018.11.003</pub-id><pub-id pub-id-type="pmid">30902255</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>F</given-names></name><name><surname>Palte</surname><given-names>IC</given-names></name><name><surname>Gontarz</surname><given-names>PM</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptomic analysis of bone and fibrous tissue morphogenesis during digit tip regeneration in the adult mouse</article-title><source>FASEB Journal</source><volume>34</volume><fpage>9740</fpage><lpage>9754</lpage><pub-id pub-id-type="doi">10.1096/fj.202000330R</pub-id><pub-id pub-id-type="pmid">32506623</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raudvere</surname><given-names>U</given-names></name><name><surname>Kolberg</surname><given-names>L</given-names></name><name><surname>Kuzmin</surname><given-names>I</given-names></name><name><surname>Arak</surname><given-names>T</given-names></name><name><surname>Adler</surname><given-names>P</given-names></name><name><surname>Peterson</surname><given-names>H</given-names></name><name><surname>Vilo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>G:profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update)</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W191</fpage><lpage>W198</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz369</pub-id><pub-id pub-id-type="pmid">31066453</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rimoin</surname><given-names>DL</given-names></name><name><surname>Cohn</surname><given-names>D</given-names></name><name><surname>Krakow</surname><given-names>D</given-names></name><name><surname>Wilcox</surname><given-names>W</given-names></name><name><surname>Lachman</surname><given-names>RS</given-names></name><name><surname>Alanay</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The skeletal dysplasias: clinical-molecular correlations</article-title><source>Annals of the New York Academy of Sciences</source><volume>1117</volume><fpage>302</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1196/annals.1402.072</pub-id><pub-id pub-id-type="pmid">18056050</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rock</surname><given-names>MJ</given-names></name><name><surname>Prenen</surname><given-names>J</given-names></name><name><surname>Funari</surname><given-names>VA</given-names></name><name><surname>Funari</surname><given-names>TL</given-names></name><name><surname>Merriman</surname><given-names>B</given-names></name><name><surname>Nelson</surname><given-names>SF</given-names></name><name><surname>Lachman</surname><given-names>RS</given-names></name><name><surname>Wilcox</surname><given-names>WR</given-names></name><name><surname>Reyno</surname><given-names>S</given-names></name><name><surname>Quadrelli</surname><given-names>R</given-names></name><name><surname>Vaglio</surname><given-names>A</given-names></name><name><surname>Owsianik</surname><given-names>G</given-names></name><name><surname>Janssens</surname><given-names>A</given-names></name><name><surname>Voets</surname><given-names>T</given-names></name><name><surname>Ikegawa</surname><given-names>S</given-names></name><name><surname>Nagai</surname><given-names>T</given-names></name><name><surname>Rimoin</surname><given-names>DL</given-names></name><name><surname>Nilius</surname><given-names>B</given-names></name><name><surname>Cohn</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Gain-of-function mutations in TRPV4 cause autosomal dominant brachyolmia</article-title><source>Nature Genetics</source><volume>40</volume><fpage>999</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1038/ng.166</pub-id><pub-id pub-id-type="pmid">18587396</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saitta</surname><given-names>B</given-names></name><name><surname>Passarini</surname><given-names>J</given-names></name><name><surname>Sareen</surname><given-names>D</given-names></name><name><surname>Ornelas</surname><given-names>L</given-names></name><name><surname>Sahabian</surname><given-names>A</given-names></name><name><surname>Argade</surname><given-names>S</given-names></name><name><surname>Krakow</surname><given-names>D</given-names></name><name><surname>Cohn</surname><given-names>DH</given-names></name><name><surname>Svendsen</surname><given-names>CN</given-names></name><name><surname>Rimoin</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Patient-Derived skeletal dysplasia induced pluripotent stem cells display abnormal chondrogenic marker expression and regulation by BMP2 and TGFβ1</article-title><source>Stem Cells and Development</source><volume>23</volume><fpage>1464</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1089/scd.2014.0014</pub-id><pub-id pub-id-type="pmid">24559391</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>A</given-names></name><name><surname>Werheid</surname><given-names>DF</given-names></name><name><surname>Knapp</surname><given-names>SM</given-names></name><name><surname>Tobiasch</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Role of Hox genes in stem cell differentiation</article-title><source>World Journal of Stem Cells</source><volume>7</volume><fpage>583</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.4252/wjsc.v7.i3.583</pub-id><pub-id pub-id-type="pmid">25914765</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>P</given-names></name><name><surname>Markiel</surname><given-names>A</given-names></name><name><surname>Ozier</surname><given-names>O</given-names></name><name><surname>Baliga</surname><given-names>NS</given-names></name><name><surname>Wang</surname><given-names>JT</given-names></name><name><surname>Ramage</surname><given-names>D</given-names></name><name><surname>Amin</surname><given-names>N</given-names></name><name><surname>Schwikowski</surname><given-names>B</given-names></name><name><surname>Ideker</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title><source>Genome Research</source><volume>13</volume><fpage>2498</fpage><lpage>2504</lpage><pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id><pub-id pub-id-type="pmid">14597658</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sophia Fox</surname><given-names>AJ</given-names></name><name><surname>Bedi</surname><given-names>A</given-names></name><name><surname>Rodeo</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The basic science of articular cartilage: structure, composition, and function</article-title><source>Sports Health</source><volume>1</volume><fpage>461</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1177/1941738109350438</pub-id><pub-id pub-id-type="pmid">23015907</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staines</surname><given-names>KA</given-names></name><name><surname>Mackenzie</surname><given-names>NCW</given-names></name><name><surname>Clarkin</surname><given-names>CE</given-names></name><name><surname>Zelenchuk</surname><given-names>L</given-names></name><name><surname>Rowe</surname><given-names>PS</given-names></name><name><surname>MacRae</surname><given-names>VE</given-names></name><name><surname>Farquharson</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>MEPE is a novel regulator of growth plate cartilage mineralization</article-title><source>Bone</source><volume>51</volume><fpage>418</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2012.06.022</pub-id><pub-id pub-id-type="pmid">22766095</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strzelecka- Kiliszek</surname><given-names>A</given-names></name><name><surname>Bożycki</surname><given-names>Ł</given-names></name><name><surname>Dudek</surname><given-names>J</given-names></name><name><surname>Gasik</surname><given-names>J</given-names></name><name><surname>Pikuła</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pęcherzyki transportu wewnątrzkomórkowego I zewnątrzkomórkowego – kluczowe struktury W procesie różnicowania tkanki kostnej I chrzęstnej</article-title><source>Postępy Biochemii</source><volume>64</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.18388/pb.2018_137</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Superti-Furga</surname><given-names>A</given-names></name><name><surname>Unger</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Nosology and classification of genetic skeletal disorders: 2006 revision</article-title><source>American Journal of Medical Genetics. Part A</source><volume>143A</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.31483</pub-id><pub-id pub-id-type="pmid">17120245</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taillandier</surname><given-names>A</given-names></name><name><surname>Domingues</surname><given-names>C</given-names></name><name><surname>De Cazanove</surname><given-names>C</given-names></name><name><surname>Porquet-Bordes</surname><given-names>V</given-names></name><name><surname>Monnot</surname><given-names>S</given-names></name><name><surname>Kiffer-Moreira</surname><given-names>T</given-names></name><name><surname>Rothenbuhler</surname><given-names>A</given-names></name><name><surname>Guggenbuhl</surname><given-names>P</given-names></name><name><surname>Cormier</surname><given-names>C</given-names></name><name><surname>Baujat</surname><given-names>G</given-names></name><name><surname>Debiais</surname><given-names>F</given-names></name><name><surname>Capri</surname><given-names>Y</given-names></name><name><surname>Cohen-Solal</surname><given-names>M</given-names></name><name><surname>Parent</surname><given-names>P</given-names></name><name><surname>Chiesa</surname><given-names>J</given-names></name><name><surname>Dieux</surname><given-names>A</given-names></name><name><surname>Petit</surname><given-names>F</given-names></name><name><surname>Roume</surname><given-names>J</given-names></name><name><surname>Isnard</surname><given-names>M</given-names></name><name><surname>Cormier-Daire</surname><given-names>V</given-names></name><name><surname>Linglart</surname><given-names>A</given-names></name><name><surname>Millán</surname><given-names>JL</given-names></name><name><surname>Salles</surname><given-names>J-P</given-names></name><name><surname>Muti</surname><given-names>C</given-names></name><name><surname>Simon-Bouy</surname><given-names>B</given-names></name><name><surname>Mornet</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Molecular diagnosis of hypophosphatasia and differential diagnosis by targeted next generation sequencing</article-title><source>Molecular Genetics and Metabolism</source><volume>116</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2015.09.010</pub-id><pub-id pub-id-type="pmid">26432670</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Tanabe</surname><given-names>K</given-names></name><name><surname>Ohnuki</surname><given-names>M</given-names></name><name><surname>Narita</surname><given-names>M</given-names></name><name><surname>Ichisaka</surname><given-names>T</given-names></name><name><surname>Tomoda</surname><given-names>K</given-names></name><name><surname>Yamanaka</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</article-title><source>Cell</source><volume>131</volume><fpage>861</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.11.019</pub-id><pub-id pub-id-type="pmid">18035408</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Holten</surname><given-names>J</given-names></name><name><surname>Reedquist</surname><given-names>K</given-names></name><name><surname>Sattonet-Roche</surname><given-names>P</given-names></name><name><surname>Smeets</surname><given-names>TJ</given-names></name><name><surname>Plater-Zyberk</surname><given-names>C</given-names></name><name><surname>Vervoordeldonk</surname><given-names>MJ</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis</article-title><source>Arthritis Res Ther</source><volume>6</volume><fpage>R239</fpage><lpage>R249</lpage><pub-id pub-id-type="doi">10.1186/ar1165</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volpe</surname><given-names>MV</given-names></name><name><surname>Ramadurai</surname><given-names>SM</given-names></name><name><surname>Mujahid</surname><given-names>S</given-names></name><name><surname>Vong</surname><given-names>T</given-names></name><name><surname>Brandao</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>KT</given-names></name><name><surname>Nielsen</surname><given-names>HC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Regulatory interactions between androgens, hoxb5, and TGFβsignaling in murine lung development</article-title><source>BioMed Research International</source><volume>1</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1155/2013/320249</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Votava</surname><given-names>L</given-names></name><name><surname>Schwartz</surname><given-names>AG</given-names></name><name><surname>Harasymowicz</surname><given-names>NS</given-names></name><name><surname>Wu</surname><given-names>CL</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Effects of dietary fatty acid content on humeral cartilage and bone structure in a mouse model of diet-induced obesity</article-title><source>Journal of Orthopaedic Research</source><volume>37</volume><fpage>779</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1002/jor.24219</pub-id><pub-id pub-id-type="pmid">30644575</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>RSeQC: quality control of RNA-seq experiments</article-title><source>Bioinformatics</source><volume>28</volume><fpage>2184</fpage><lpage>2185</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts356</pub-id><pub-id pub-id-type="pmid">22743226</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstein</surname><given-names>MM</given-names></name><name><surname>Tompson</surname><given-names>SW</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Cohn</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mice expressing mutant TRPV4 recapitulate the human TRPV4 disorders</article-title><source>Journal of Bone and Mineral Research</source><volume>29</volume><fpage>1815</fpage><lpage>1822</lpage><pub-id pub-id-type="doi">10.1002/jbmr.2220</pub-id><pub-id pub-id-type="pmid">24644033</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wellik</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2009">2009</year><chapter-title>Chapter 9 <italic>Hox</italic> genes and vertebrate axial pattern</chapter-title><source>Current Topics in Developmental Biology</source><publisher-name>Elsevier</publisher-name><fpage>257</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/S0070-2153(09)88009-5</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><source>Ggplot2: Elegant Graphics for Data Analysis</source><edition>1 ed</edition><publisher-loc>New York</publisher-loc><publisher-name>Springer-Verlag</publisher-name><pub-id pub-id-type="doi">10.1007/978-0-387-98141-3</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willard</surname><given-names>VP</given-names></name><name><surname>Leddy</surname><given-names>HA</given-names></name><name><surname>Palmer</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>CL</given-names></name><name><surname>Liedtke</surname><given-names>W</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transient receptor potential vanilloid 4 as a regulator of induced pluripotent stem cell chondrogenesis</article-title><source>Stem Cells</source><volume>39</volume><fpage>1447</fpage><lpage>1456</lpage><pub-id pub-id-type="doi">10.1002/stem.3440</pub-id><pub-id pub-id-type="pmid">34427363</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilusz</surname><given-names>RE</given-names></name><name><surname>Zauscher</surname><given-names>S</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Micromechanical mapping of early osteoarthritic changes in the pericellular matrix of human articular cartilage</article-title><source>Osteoarthritis and Cartilage</source><volume>21</volume><fpage>1895</fpage><lpage>1903</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2013.08.026</pub-id><pub-id pub-id-type="pmid">24025318</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>S</given-names></name><name><surname>Humphreys</surname><given-names>PA</given-names></name><name><surname>Bates</surname><given-names>N</given-names></name><name><surname>Richardson</surname><given-names>SA</given-names></name><name><surname>Kuba</surname><given-names>SY</given-names></name><name><surname>Brooks</surname><given-names>IR</given-names></name><name><surname>Cain</surname><given-names>SA</given-names></name><name><surname>Kimber</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Regulation of TGFβ signalling by TRPV4 in chondrocytes</article-title><source>Cells</source><volume>10</volume><elocation-id>726</elocation-id><pub-id pub-id-type="doi">10.3390/cells10040726</pub-id><pub-id pub-id-type="pmid">33805168</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CL</given-names></name><name><surname>Dicks</surname><given-names>A</given-names></name><name><surname>Steward</surname><given-names>N</given-names></name><name><surname>Tang</surname><given-names>R</given-names></name><name><surname>Katz</surname><given-names>DB</given-names></name><name><surname>Choi</surname><given-names>YR</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Single cell transcriptomic analysis of human pluripotent stem cell chondrogenesis</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>362</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-20598-y</pub-id><pub-id pub-id-type="pmid">33441552</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yammani</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>S100 proteins in cartilage: role in arthritis</article-title><source>Biochimica et Biophysica Acta</source><volume>1822</volume><fpage>600</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2012.01.006</pub-id><pub-id pub-id-type="pmid">22266138</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>ZX</given-names></name><name><surname>Song</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Toward a better understanding of type I interferonopathies: a brief summary, update and beyond</article-title><source>World Journal of Pediatrics</source><volume>16</volume><fpage>44</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1007/s12519-019-00273-z</pub-id><pub-id pub-id-type="pmid">31377974</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zelenski</surname><given-names>NA</given-names></name><name><surname>Leddy</surname><given-names>HA</given-names></name><name><surname>Sanchez-Adams</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Bonaldo</surname><given-names>P</given-names></name><name><surname>Liedtke</surname><given-names>W</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Type VI collagen regulates pericellular matrix properties, chondrocyte swelling, and mechanotransduction in mouse articular cartilage</article-title><source>Arthritis &amp; Rheumatology</source><volume>67</volume><fpage>1286</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1002/art.39034</pub-id><pub-id pub-id-type="pmid">25604429</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>NN</given-names></name><name><surname>Zhou</surname><given-names>XW</given-names></name><name><surname>Miao</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>CY</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>QW</given-names></name><name><surname>Zhang</surname><given-names>JY</given-names></name><name><surname>Nie</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Xiao</surname><given-names>LB</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>JR</given-names></name><name><surname>Zhang</surname><given-names>DQ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Exogenous IFN-beta regulates the RANKL-c-fos-IFN-beta signaling pathway in the collagen antibody-induced arthritis model</article-title><source>Journal of Translational Medicine</source><volume>12</volume><elocation-id>330</elocation-id><pub-id pub-id-type="doi">10.1186/s12967-014-0330-y</pub-id><pub-id pub-id-type="pmid">25491303</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>TPRV4</italic>; Transient Receptor Potential Cation Channel Subfamily V Member 4</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18083">HGNC:18083</ext-link>; ENSEMBL:ENSG00000111199</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>SOX9</italic>; SRY-box transcription factor 9</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11204">HGNC:11204</ext-link>; ENSEMBL:ENSG00000125398</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>RUNX2</italic>; RUNX family transcription factor 2</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10472">HGNC:10472</ext-link>; ENSEMBL:ENSG00000124813</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>FST</italic>; follistatin</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3971">HGNC:3971</ext-link>; ENSEMBL:ENSG00000134363</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>ACAN</italic>; aggrecan</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:319">HGNC:319</ext-link>; ENSEMBL:ENSG00000157766</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>COL2A1</italic>; collagen type II alpha 1 chain</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2200">HGNC:2200</ext-link>; ENSEMBL:ENSG00000139219</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>S100B</italic>; S100 calcium-binding protein B</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10500">HGNC:10500</ext-link>; ENSEMBL:ENSG00000160307</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>COL1A1</italic>; collagen type I alpha 1 chain</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2197">HGNC:2197</ext-link>; ENSEMBL:ENSG00000108821</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>COL10A1</italic>; collagen type X alpha 1 chain</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2185">HGNC:2185</ext-link>; ENSEMBL:ENSG00000123500</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>ALPL</italic>; alkaline phosphatase, biomineralization associated</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:438">HGNC:438</ext-link>; ENSEMBL:ENSG00000162551</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>IHH</italic>; Indian hedgehog signaling molecule</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5956">HGNC:5956</ext-link>; ENSEMBL:ENSG00000163501</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>GSTA1</italic>; glutathione <italic>S</italic>-transferase alpha 1</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4626">HGNC:4626</ext-link>; ENSEMBL:ENSG00000243955</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>AMELX</italic>; amelogenin X-linked</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:461">HGNC:461</ext-link>; ENSEMBL:ENSG00000125363</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>IFITM5</italic>; interferon induced transmembrane protein 5</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16644">HGNC:16644</ext-link>; ENSEMBL:ENSG00000206013</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>IBSP</italic>; integrin-binding sialoprotein</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5341">HGNC:5341</ext-link>; ENSEMBL:ENSG00000029559</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom"><italic>MEPE</italic>; matrix extracellular phosphoglycoprotein</td><td align="left" valign="bottom">HGNC Symbol</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13361">HGNC:13361</ext-link>; ENSEMBL:ENSG00000152595</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom">BJFF.6; BJFF</td><td align="left" valign="bottom">Washington University Genome Engineering and iPSC Center</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_VU02">CVCL_VU02</ext-link></td><td align="left" valign="bottom">Induced pluripotent stem cell derived from foreskin fibroblast</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom">V620I</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Washington University Genome Engineering and iPSC Center; CRISPR-edited BJFF.6 with V620I TRPV4 mutation</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapien</italic>)</td><td align="left" valign="bottom">T89I</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Washington University Genome Engineering and iPSC Center; CRISPR-edited BJFF.6 with T89I TRPV4 mutation</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Human Alkaline Phosphatase/ALPL Antibody; Anti-ALPL (mouse monoclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat #: MAB29092; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2924405">AB_2924405</ext-link></td><td align="left" valign="bottom">WB (1:3000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Collagen I antibody; Anti-COL1A1 (mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat #: ab90395; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2049527">AB_2049527</ext-link></td><td align="left" valign="bottom">IHC P (1:800); pepsin retrieval (5 min, RT)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Collagen type II: Anti-COL2A1 (mouse monoclonal)</td><td align="left" valign="bottom">Iowa Hybridoma Bank</td><td align="left" valign="bottom">Cat #: II-II6B3-s; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_528165">AB_528165</ext-link></td><td align="left" valign="bottom">IHC P (1:10); proteinase k retrieval (3 min, 37°C)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Collagen Type VI antibody; Anti-COL6A1 (rabbit polyclonal)</td><td align="left" valign="bottom">Fitzgerald Industries</td><td align="left" valign="bottom">Cat #: 70F-CR009X; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1283876">AB_1283876</ext-link></td><td align="left" valign="bottom">IHC P (1:1000); proteinase k retrieval (3 min, 37°C)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Monoclonal Anti-Collagen, Type X antibody produced in mouse; Anti-COL10A1 (mouse monoclonal)</td><td align="left" valign="bottom">Millipore Sigma</td><td align="left" valign="bottom">Cat #: C7974; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_259075">AB_259075</ext-link></td><td align="left" valign="bottom">IHC P (1:200); pepsin retrieval (5 min, RT)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Collagen X Polyclonal Antibody; anti-COL10A1 (rabbit polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat #: PA5-97603; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2812218">AB_2812218</ext-link></td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">GAPDH Monoclonal antibody; anti-GAPDH (mouse monoclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat #: 60004-1-Ig; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2107436">AB_2107436</ext-link></td><td align="left" valign="bottom">WB (1:30,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IHH Monoclonal Antibody (363CT4.1.6); Anti-IHH (mouse monoclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat #: MA5-37541; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2897471">AB_2897471</ext-link></td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">MMP13 Monoclonal Antibody (VIIIA2); Anti-MMP13 (mouse monoclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat #: MA5-14238; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10981616">AB_10981616</ext-link></td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">RUNX2 Monoclonal Antibody (ZR002); Anti-RUNX2 (mouse monoclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat #: 41-1400 RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2533497">AB_2533497</ext-link></td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IgG, HRP-linked antibody; horse anti-mouse IgG secondary antibody (horse polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat #: 7076; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330924">AB_330924</ext-link></td><td align="left" valign="bottom">WB (1:30,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat Anti-Mouse IgG H&amp;L (Biotin); Goat anti-mouse antibody (goat polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat #: ab97021; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10679674">AB_10679674</ext-link></td><td align="left" valign="bottom">IHC (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat Anti-Rabbit IgG H&amp;L (Biotin); Goat anti-rabbit antibody (goat polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat #: ab6720; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_954902">AB_954902</ext-link></td><td align="left" valign="bottom">IHC (1:500)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">ACAN_F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib36">Huynh et al., 2020</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CACTTCTGAGTTCGTGGAGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">ACAN_R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib36">Huynh et al., 2020</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ACTGGACTCAAAAAGCTGGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">COL1A1_F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Adkar et al., 2019</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TGTTCAGCTTTGTGGACCTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">COL1A1_R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Adkar et al., 2019</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TTCTGTACGCAGGTGATTGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">COL2A1_F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Adkar et al., 2019</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GGCAATAGCAGGTTCACGTA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">COL2A1_R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Adkar et al., 2019</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CTCGATAACAGTCTTGCCCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">COL10A1_F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Adkar et al., 2019</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CATAAAAGGCCCACTACCCAAC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">COL10A1_R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Adkar et al., 2019</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ACCTTGCTCTCCTCTTACTGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">FST_F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib75">Ohta et al., 2015</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TGTGCCCTGACAGTAAGTCG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">FST_R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib75">Ohta et al., 2015</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GTCTTCCGAAATGGAGTTGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">S100B_F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib23">Dix et al., 2016</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AGGGAGGGAGACAAGCACAA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">S100B_R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib23">Dix et al., 2016</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ACTCGTGGCAGGCAGTAGTA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">SOX9_F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib54">Loh et al., 2016</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CGTCAACGGCTCCAGCAAGAACAA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">SOX9_R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib54">Loh et al., 2016</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCCGCTTCTCGCTCTCGTTCAGAAGT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TRPV4_F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib59">Luo et al., 2018</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AGAACTTGGGCATCATCAACGAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TRPV4_R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib59">Luo et al., 2018</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GTTCGAGTTCTTGTTCAGTTCCAC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TBP_F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Adkar et al., 2019</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AACCACGGCACTGATTTTCA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TBP_R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Adkar et al., 2019</xref></td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ACAGCTCCCCACCATATTCT</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Vitronectin; VTN-N</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat #: A14700</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Activin</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat #: 338-AC</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Fibroblastic growth factor 2; FGF2</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat #: 233-FB-025/CF</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Bone morphogenetic protein 4; BMP4</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat #: 314-BP-010CF</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Human transforming growth factor- <inline-formula><mml:math id="inf1"><mml:mi>β</mml:mi></mml:math></inline-formula> 3; TGF <inline-formula><mml:math id="inf2"><mml:mi>β</mml:mi></mml:math></inline-formula> 3</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat #: 243-B3-010/CF</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Type II collagenase</td><td align="left" valign="bottom">Worthington Biochemical</td><td align="left" valign="bottom">Cat #: LS00417</td><td align="left" valign="bottom">Activity 225 u/ML</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Fluo-4 AM</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat #: F14201</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Fura Red AM</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat #: F3021</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Quant-iT PicoGreen dsDNA Assay Kit; PicoGreen</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat #: P7589</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Total RNA Purification Plus Kit</td><td align="left" valign="bottom">Norgen Biotek</td><td align="left" valign="bottom">Cat #: 48400</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Fast SYBR green</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat #: 4385610</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Histostain Plus Kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat #: 858943</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">AEC substrate solution</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat #: ab64252</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Y-27632</td><td align="left" valign="bottom">STEMCELL Technologies</td><td align="left" valign="bottom">Cat #: 72304</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ReLeSR</td><td align="left" valign="bottom">STEMCELL Technologies</td><td align="left" valign="bottom">Cat #: 053263872</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CHIR99021</td><td align="left" valign="bottom">Reprocell</td><td align="left" valign="bottom">Cat #: 04-0004-02</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SB505124</td><td align="left" valign="bottom">Tocris Bioscience</td><td align="left" valign="bottom">Cat #: 3263</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dorsomorphin; DM</td><td align="left" valign="bottom">Reprocell</td><td align="left" valign="bottom">Cat #: 04-0024</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PD173074</td><td align="left" valign="bottom">Tocris Bioscience</td><td align="left" valign="bottom">Cat #: 3044</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Wnt-C59</td><td align="left" valign="bottom">Cellagen Technologies</td><td align="left" valign="bottom">Cat #: C7641-2s</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Purmorphamine</td><td align="left" valign="bottom">Reprocell</td><td align="left" valign="bottom">Cat #: 04-0009</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">1-Thioglycerol</td><td align="left" valign="bottom">Millipore Sigma</td><td align="left" valign="bottom">Cat #: M6145</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2-Mercaptoethnol; 2-ME</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Gibco; Cat #: 21985023</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom"><sc>L</sc>-Ascorbic acid; ascorbate</td><td align="left" valign="bottom">Millipore Sigma</td><td align="left" valign="bottom">Cat #: A89<break/><break/>60</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom"><sc>L</sc>-Proline; proline</td><td align="left" valign="bottom">Millipore Sigma</td><td align="left" valign="bottom">Cat #: P5607</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ML329</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat #: 2248</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dexamethasone; Dex</td><td align="left" valign="bottom">Millipore Sigma</td><td align="left" valign="bottom">Cat #: D4902</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">GSK1016790A; GSK101</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat #: G0798</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">GSK205</td><td align="left" valign="bottom">AOBIOUS</td><td align="left" valign="bottom">Cat #: AOB1612 1263130-79-5</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sulfinpyrazone</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat #: S9509-5G</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">1,9-Dimethylmethylene blue; DMMB</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat #: 341088</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">pClamp software suite</td><td align="left" valign="bottom">Molecular Devices</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_011323">SCR_011323</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Fiji software – ImageJ</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002285">SCR_002285</ext-link>; version 2.1.0</td><td align="left" valign="bottom">Used to analyze fluorescence confocal imaging of calcium signaling</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MATLAB – Hertz model</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib17">Darling et al., 2006</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Used to analyze AFM data to determine modulus</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">bcl2fastq</td><td align="left" valign="bottom">llumina</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015058">SCR_015058</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Ensembl release 76 primary assembly with STAR</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Dobin et al., 2013</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002344">SCR_002344</ext-link>; version 2.5.1a</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Subread:featureCount</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib52">Liao et al., 2014</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_012919">SCR_012919</ext-link>; version 1.4.6-p5</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Salmon</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib79">Patro et al., 2017</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_017036">SCR_017036</ext-link>; version 0.8.2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">RSeQC</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib99">Wang et al., 2012</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_005275">SCR_005275</ext-link>; version 2.6.2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">DESeq2 R package</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib56">Love et al., 2014</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015687">SCR_015687</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Pheatmap R package</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib43">Kolde, 2015</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016418">SCR_016418</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ggplot2 R package</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib102">Wickham, 2009</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014601">SCR_014601</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism, version 9.1</td><td align="left" valign="bottom">GraphPad Software, Boston, MA</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link>; version 9.1.0</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">VennDiagram R package</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib13">Chen and Boutros, 2011</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002414">SCR_002414</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">g:profiler</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib84">Raudvere et al., 2019</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_006809">SCR_006809</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">tidyverse R package</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib3">Altman and Krzywinski, 2017</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_019186">SCR_019186</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Cytoscape String</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib25">Doncheva et al., 2019</xref>; <xref ref-type="bibr" rid="bib89">Shannon et al., 2003</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003032">SCR_003032</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Essential 8 Flex Media; E8</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Gibco; Cat #: A2858501</td><td align="left" valign="bottom">hiPSC medium (see Materials and methods: hiPSC culture)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Iscove’s Modified Dulbecco’s Medium, glutaMAX; IMDM</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Gibco; Cat #: 31980097</td><td align="left" valign="bottom">Mesodermal differentiation medium (see Materials and methods: Mesodermal differentiation)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Ham’s F-12 nutrient mix, glutaMAX; F12</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Gibco; Cat #: 31765092</td><td align="left" valign="bottom">Mesodermal differentiation medium (see Materials and methods: Mesodermal differentiation)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Penicillin–streptomycin; P/S</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Gibco; Cat #: 15140122</td><td align="left" valign="bottom">Mesodermal and chondrogenic differentiation medium supplement (see Materials and methods: Mesodermal differentiation, Chondrogenic differentiation with 3D pellet culture)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Insulin–Transferrin–Selenium; ITS+</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Gibco; Cat #: 41400045</td><td align="left" valign="bottom">Mesodermal and chondrogenic differentiation medium supplement (see Materials and methods: Mesodermal differentiation, Chondrogenic differentiation with 3D pellet culture)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Chemically defined concentrated lipids</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat #: 11905031</td><td align="left" valign="bottom">Mesodermal differentiation medium supplement (see Materials and methods: Mesodermal differentiation)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Dulbecco’s Modified Eagle Medium/F12, glutaMAX; DMEM/F12</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat #: 10565042</td><td align="left" valign="bottom">Chondrogenic differentiation medium (see Materials and methods: Chondrogenic differentiation with 3D pellet culture)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Modified Eagle Medium (MEM) with nonessential amino acids; NEAA</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Gibco; Cat #: 11140050</td><td align="left" valign="bottom">Chondrogenic differentiation medium supplement (see Materials and methods: Chondrogenic differentiation with 3D pellet culture)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Fetal bovine serum; FBS</td><td align="left" valign="bottom">Atlanta Biologicals</td><td align="left" valign="bottom">Cat #: S11550</td><td align="left" valign="bottom">Neutralization medium (see Materials and methods: Chondrogenic differentiation with 3D pellet culture)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Axopatch 1D patch-clamp amplifier and digitized with Digidata 1320 digitizer</td><td align="left" valign="bottom">Molecular Devices</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Patch clamping equipment (see Materials and methods: Patch clamping)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Soda lime glass</td><td align="left" valign="bottom">Kimble Chase</td><td align="left" valign="bottom">Cat #: 2502</td><td align="left" valign="bottom">Patch clamping equipment (see Materials and methods: Patch clamping)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Sutter P-86 puller</td><td align="left" valign="bottom">Sutter Instruments</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Patch clamping equipment (see Materials and methods: Patch clamping)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">HEPES</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Gibco; Cat #: 15630130</td><td align="left" valign="bottom">Calcium signaling medium (see Materials and methods: TRPV4 agonists and antagonists, Patch clamping)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Confocal microscope</td><td align="left" valign="bottom">Zeiss</td><td align="left" valign="bottom">LSM 880</td><td align="left" valign="bottom">Calcium signaling equipment (see Materials and methods: Confocal imaging of Ca<sup>2+</sup> signaling)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Optimal cutting temperature; OCT</td><td align="left" valign="bottom">Sakura Finetek</td><td align="left" valign="bottom">Cat #: 4583</td><td align="left" valign="bottom">AFM materials (see Materials and methods: AFM measurement of neocartilage mechanical properties)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Cryofilm</td><td align="left" valign="bottom">Section-Lab</td><td align="left" valign="bottom">Type: 2C(10)</td><td align="left" valign="bottom">AFM materials (see Materials and methods: AFM measurement of neocartilage mechanical properties)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Atomic force microscopy; AFM</td><td align="left" valign="bottom">Asylum Research</td><td align="left" valign="bottom">Cat #: MFP-3D Bio</td><td align="left" valign="bottom">AFM equipment (see Materials and methods: AFM measurement of neocartilage mechanical properties)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Silicon cantilever with a spherical tip</td><td align="left" valign="bottom">Novascan Technologies</td><td align="left" valign="bottom"/><td align="left" valign="bottom">5 μm diameter, <italic>k</italic> ~ 7.83 N/m; AFM materials (see Materials and methods: AFM measurement of neocartilage mechanical properties)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">RIPA buffer</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat #: 9806S</td><td align="left" valign="bottom">Western blot materials (see Materials andmethods: Western blot)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Protease inhibitor</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat #: 87786</td><td align="left" valign="bottom">Western blot materials (see Materials and methods: Western blot)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">TidyBlot Western Blot Detection Reagent:HRP; TidyBlot-Reagent-HRP</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">Cat #: STAR209</td><td align="left" valign="bottom">1:1000; Western blot materials (see Materials and methods: Western blot)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis gel with pre-stained molecular weight markers</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">Cat #: 161-0374</td><td align="left" valign="bottom">Western blot materials (see Materials and methods: Western blot)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">iBright FL1000 Imaging System</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Western blot equipment (see Materials and methods: Western blot)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">DNase</td><td align="left" valign="bottom">Norgen Biotek</td><td align="left" valign="bottom">Cat #: 25720</td><td align="left" valign="bottom">RNA sequencing materials (see Materials and methods: Genome-wide mRNA sequencing)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">RNA Clean-Up and Concentration Kit</td><td align="left" valign="bottom">Norgen Biotek</td><td align="left" valign="bottom">Cat #: 43200</td><td align="left" valign="bottom">RNA sequencing materials (see Materials and methods: Genome-wide mRNA sequencing)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">NovaSeq 6000</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom"/><td align="left" valign="bottom">RNA sequencing equipment (see Materials and methods: Genome-wide mRNA sequencing)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Safranin-O solution; Saf-O</td><td align="left" valign="bottom">Millipore Sigma</td><td align="left" valign="bottom">Cat #: HT904</td><td align="left" valign="bottom">Histology materials (see Materials and methods: Histology)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Harris hematoxylin with glacial acetic acid; hematoxylin</td><td align="left" valign="bottom">Poly Scientific</td><td align="left" valign="bottom">Cat #: 212A16OZ</td><td align="left" valign="bottom">Histology materials (see Materials and methods: Histology)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Vector hematoxilyn QS counterstain</td><td align="left" valign="bottom">Vector Laboratories</td><td align="left" valign="bottom">Cat #: H-3404</td><td align="left" valign="bottom">Histology materials (see Materials and methods: Histology)</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.71154.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Di</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/034t30j35</institution-id><institution>Chinese Academy of Sciences</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2021.06.15.448562" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2021.06.15.448562"/></front-stub><body><p>Analysis of different types of TRPV4 mutant hiPS cells (mild V620I vs severe T89I mutations) showed alterations in calcium channel function and chondrocyte differentiation. hiPSC-derived chondrocytes with the V620I mutation exhibited increased basal currents through TRPV4, while both mutations showed more rapid calcium signaling with a reduced overall magnitude in response to TRPV4 agonist GSK1016790A compared to wild-type cells. These findings provide potential therapeutic targets for developing treatments for TRPV4-mediated skeletal dysplasias.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.71154.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Chen</surname><given-names>Di</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/034t30j35</institution-id><institution>Chinese Academy of Sciences</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Chen</surname><given-names>Di</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/034t30j35</institution-id><institution>Chinese Academy of Sciences</institution></institution-wrap><country>China</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.06.15.448562">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.06.15.448562v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Skeletal dysplasia-causing TRPV4 mutations suppress the hypertrophic differentiation of human iPSC-derived chondrocytes&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Di Chen as the Reviewing Editor and Reviewer #3, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) The authors need to consider analyzing changes in TRPV4 phosphorylation in V620I and T89I mutant cells.</p><p>2) In order to confirm the changes in chondrocyte hypertrophy, the authors need to analyze the expression of other markers, such as Runx2, MMP13, and Ihh.</p><p>3) To confirm RNA-seq data, RT-PCR verification is recommended.</p><p>4) Additional data are required to support the conclusion that the mutations of V620I and T89I are indeed different. Only minor differences were identified from the current study.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. In addition to evaluating the electrophysiology of chondrocytes as a functional assessment, the analysis of differences in TRPV4 activation i.e. phosphorylation (like the study by Cao et al. in JBC 2018; 294:5307) should be considered to confirm V620I and T89I mutation-induced changes in TRPV4 activities.</p><p>2. The results of 42-day-induction chondrocytes were either little- or non-described in this report. It seems like the data when included make it more challenging to interpret the findings. Will the authors consider repeating the experiment to verify the results or simply removing the data?</p><p>3. The key finding shown here is the TRPV4 mutations inhibit chondrocyte hypertrophy. In addition to cell size and COL10 expression, it should be considered to include other data such as the expression of markers, RUX2, MMP13, and IHH for the confirmation of chondrocyte hypertrophy.</p><p>4. It is known that RNA-seq measures a rough expression level of a transcript so RT-PCR verification is often performed. Therefore, the RT-PCR analysis of expression levels of the identified genes, ALPL, AMELX, IFITM5, and others, should be considered as an addition to Figure 6.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>In this manuscript, Dicks et al. generated two human iPSC lines with TRPV4 mutations (mild V620I or lethal T89I) using a CRISPR-Cas9 approach and examined their channel function and differentiation abilities into chondrocytes. While their initial goal is to elucidate the detailed molecular mechanisms underlying how these two mutations lead to strikingly distinct severities of skeletal dysplasias, most of their data found that these two mutations behave in a similar manner. The minor differences they found are: 1) increased basal currents in V620I cells; 2) reduced mechanical properties of cartilage matrix in V620I chondrocytes; 3) some differences in DEGs of RNA-seq data. They also stated that &quot;The severe T89I mutation inhibits chondrocyte hypertrophy more than moderate V620I 298 mutation&quot; (page 16). However, no substantiated data were provided to support this conclusion. While a serial of RNA-seq experiments were performed to explore the underlying mechanism, they were not followed by validation experiments to pinpoint the exact pathways or molecular mechanisms. Thus, although using CRISPR-Cas9 and iPSCs are novel and potentially important, this manuscript is overall descriptive with limited mechanistic information.</p><p>To the editor, I am not familiar with channel function assays. Please find an expert to review this part.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>TRPV4 is an ion channel protein and mutations in TRPV4 gene resulted in different types of skeletal defects. In this study, the authors created two types of TRPV4 mutations (mild V620I and lethal T89I mutations) in human iPS cells through CRISPR-Cas9 gene editing. They found that mutations of TRPV4 accelerated calcium signaling and reduced response of calcium signaling to TRPV4 agonist. In addition, the V620I mutation led to decreased mechanical properties of cartilage matrix later in chondrogenesis. TRPV4 mutations also upregulated HOX genes and downregulated antioxidant genes, such as CAT and GSTA1, through entire chondrogenesis process. BMP4-induced chondrocyte hypertrophy was also inhibited in TRPV4 mutant cells. This study provided novel information about the functions of TRPV4 in chondrogenesis and help us understand the skeletal dysplasia observed in patients with TRPV4 mutations.</p><p>The study was well designed with novel approach and state-of-the -art technology. The experiments were well executed and information gained from this study is valuable. To further improve this manuscript, few suggestions need to be considered.</p><p>1)In this study, several chndrogenic marker genes were altered in TRPV4 mutant cells and these genes are regulated by Runx2, such as Col10a1. It is not clear if Runx2 expression is changed in TRPV4 mutant cells.</p><p>2)The authors found changes in Wnt3a, Wnt7a and Wnt7b expression in TRPV4 mutant cells. Do the authors know if β-catenin protein levels were altered in TRPV4 mutant cells.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.71154.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The authors need to consider analyzing changes in TRPV4 phosphorylation in V620I and T89I mutant cells.</p></disp-quote><p>We appreciate the suggestion to look at alterations in TRPV4 phosphorylation in the mutated V620I and T89I lines and how that may be affecting TRPV4 activation. Since we know phosphorylation of TRPV4 by PKC and PKA results in altered sensitization (Cao et al., 2018; Fan, Zhang, &amp; McNaughton, 2009; Peng et al., 2010), we investigated their gene expression using our day-28 RNAseq dataset. <italic>PRKCA</italic>, the gene encoding for protein kinase C α, was upregulated in V620I compared to WT at day 28. Therefore, phosphorylation of TRPV4 by PKC could explain the increased basal calcium signaling in V620I. Unfortunately, there are no commercially available antibodies to perform a western blot and investigate phosphorylated TRPV4; however, we believe this could make for an interesting follow-up study. This data has been added to Figure 4 – Figure S1B, and its relationship to TRPV4 signaling is discussed.</p><disp-quote content-type="editor-comment"><p>2) In order to confirm the changes in chondrocyte hypertrophy, the authors need to analyze the expression of other markers, such as Runx2, MMP13, and Ihh.</p></disp-quote><p>We agree with the reviewers’ suggestions, and we have included these additional data. We believe that showing gene expression and protein production of RUNX2, <italic>MMP3</italic>, IHH, and ALPL will further support the hypertrophic differences in WT, V620I, and T89I. We have shown the gene expression using the RNA-seq data and further confirmed translation and protein production with western blots.</p><p>BMP4 treatment significantly increased expression of <italic>COL10A1</italic>, <italic>IHH</italic>, and <italic>ALPL</italic> in all three lines compared to their TGFβ3 controls; however, it only increased expression of <italic>RUNX2</italic> in WT. Surprisingly, <italic>MMP13</italic> expression was significantly decreased by BMP4 treatment in V620I and T89I lines compared to TGFβ3 controls, but there was no change in WT. WT treated with BMP4 had significantly higher expression of <italic>COL10A1</italic>, <italic>RUNX2</italic>, <italic>IHH</italic>, <italic>MMP13</italic>, and <italic>ALPL</italic> compared to V620I and T89I treated with BMP4. The moderate mutation, V620I, treated with BMP4 also had significantly higher expression of <italic>IHH</italic> and <italic>ALPL</italic> compared to the severe mutation, T89I.</p><p>These data were consistent with the western blot results. There was an increase of COL10A1, ALPL, IHH, RUNX2, and RUNX2-9 proteins with BMP4 treatment in all three lines. However, BMP4 treatment had a much stronger effect on increasing expression in WT. In support of our hypothesis that T89I had a stronger inhibitory effect on chondrogenic hypertrophy, as this mutation had lower protein production of COL10A1, ALPL, and IHH in response to BMP4 treatment compared to V620I, also consistent with the RNA-seq data. We saw the same trend in MMP13 protein and gene expression, with BMP4 causing a decrease in expression in the mutants but no change in the WT.</p><p>To strengthen our argument, we have added the western blot data to Figure 5 and included the RNA seq analysis, full blots, and quantification of the blots to Figure 5 – Figure S1.</p><disp-quote content-type="editor-comment"><p>3) To confirm RNA-seq data, RT-PCR verification is recommended.</p></disp-quote><p>We thank the reviewers for the suggestion to validate the RNA-seq data with RT-qPCR. Several groups have published that RNA-seq methods are valid and more quantitative than RT-qPCR methods, and thus do not benefit from RAT-qPCR verification (Coenye, 2021; Everaert et al., 2017). However, to confirm this point, we performed RT-qPCR on chondrogenic genes during chondrogenesis in addition to the RNA-seq performed on day-28 pellets. Here, we show that when the RT-qPCR data is analyzed in reference to either undifferentiated hiPSCs or to day-28 WT, we see similar expression patterns as the RNA-seq between WT, V620I, and T89I. Additionally, western blots were performed on hypertrophic proteins (e.g., COL10A1, ALPL, IHH, MMP13, RUNX2), and the data were consistent with the BMP4 RNA-seq data set (Figure 5 – Figure S1). Therefore, we believe that the gene expression we report based on our RNA-seq results for both day-28 and day-56 chondrogenic pellets, including those treated with BMP4, are valid.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-71154-sa2-fig1-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>4) Additional data are required to support the conclusion that the mutations of V620I and T89I are indeed different. Only minor differences were identified from the current study.</p></disp-quote><p>We appreciate the reviewer’s suggestion to dive deeper into the differences between V620I- and T89I-mutated chondrocytes. We investigated top differentially expressed genes, compared to WT, that were unique to either V620I or T89I. We found that the two lines became more divergent with continued differentiation to day 56. Upregulated genes unique to V620I included interferon induced protein with tetratricopeptide repeats 3 (<italic>IFIT3</italic>), interferon-induced GTP-binding protein Mx1 (<italic>MX1</italic>), p53 upregulated regulator of p53 levels (<italic>PURPL</italic>), and protein kinase C α (PKC; <italic>PRKCA</italic>) at day 28 and 56. Downregulated genes were related to DNA- and RNA-binding such as zinc finger proteins (<italic>ZNF736, ZNF717,</italic> and <italic>ZNF594</italic>) and ribosomal protein S4 y-linked 1 (<italic>RPS4Y1</italic>) at day 28 and 56. T89I had uniquely upregulated genes such as micro–RNA <italic>MIR1245A</italic>, dickkopf WNT signaling pathway inhibitor 2 (<italic>DKK2</italic>), and carbonic anhydrase 2 (<italic>CA2</italic>) at day 28 and insulin growth factor-like family member 3 (<italic>IGFFL3)</italic>, matrix extracellular phosphoglycoprotein (<italic>MEPE</italic>), annexin A8 (<italic>ANXA8</italic>), <italic>S100A3</italic>, and β catenin (<italic>CTNNB1</italic>) at day 56. Downregulated genes included bone sialoprotein II (<italic>IBSP</italic>) and limb development transcription factor <italic>SP9</italic> at day 28 and various zinc finger proteins at both day 28 and 56.</p><p>We also saw differences between the two lines after BMP4 treatment. This was highlighted by the unique association with biological processes for T89I compared to WT and V620I. We propose that V620I slows hypertrophic differentiation, consistent with the moderate phenotype, while T89I inhibits it, consistent with the severe phenotype. This was shown with the protein production of hypertrophic markers ALPL and IHH. While both mutants have lower production compared to WT, T89I has less than V620I.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. In addition to evaluating the electrophysiology of chondrocytes as a functional assessment, the analysis of differences in TRPV4 activation i.e. phosphorylation (like the study by Cao et al. in JBC 2018; 294:5307) should be considered to confirm V620I and T89I mutation-induced changes in TRPV4 activities.</p></disp-quote><p>We appreciate the suggestion to look at alterations in TRPV4 phosphorylation in the mutated V620I and T89I lines and how that may be affecting TRPV4 activation. Since we know phosphorylation of TRPV4 by PKC and PKA results in altered sensitization (Cao et al., 2018; Fan, Zhang, &amp; McNaughton, 2009; Peng et al., 2010), we investigated their gene expression using our day-28 RNAseq dataset. <italic>PRKCA</italic>, the gene encoding for protein kinase C α, was upregulated in V620I compared to WT at day 28. Therefore, phosphorylation of TRPV4 by PKC could explain the increased basal calcium signaling in V620I. Unfortunately, there are no commercially available antibodies to perform a western blot and investigate phosphorylated TRPV4; however, we believe this could make for an interesting follow-up study. This data has been added to Figure 4 – Figure S1B, and its relationship to TRPV4 signaling is discussed.</p><disp-quote content-type="editor-comment"><p>2. The results of 42-day-induction chondrocytes were either little- or non-described in this report. It seems like the data when included make it more challenging to interpret the findings. Will the authors consider repeating the experiment to verify the results or simply removing the data?</p></disp-quote><p>We thank the reviewer for pointing out the confusion with the day-42 data. To improve the clarity of the manuscript, we have moved the data to the supplement. The text and figures in the manuscript have been updated to reflect these changes.</p><p>We performed the differentiation through day 42 3-4 times per cell line. From our previous studies, we have found that 28 days is sufficient for chondrogenic differentiation, but we used day 42 to investigate if changes were occurring with prolonged differentiation. This data indicated there were some changes, but we ultimately decided to take the differentiation to day 56, as reported with the RNA-seq data, with and without BMP4 treatment.</p><disp-quote content-type="editor-comment"><p>3. The key finding shown here is the TRPV4 mutations inhibit chondrocyte hypertrophy. In addition to cell size and COL10 expression, it should be considered to include other data such as the expression of markers, RUX2, MMP13, and IHH for the confirmation of chondrocyte hypertrophy.</p></disp-quote><p>We agree with the reviewer that assessing additional hypertrophy markers will further confirm the differences in BMP4-induced hypertrophy. Therefore, we performed a western blot and found consistent results. BMP4 treatment increased protein production of hypertrophy markers ALPL, COL10A1, IHH, and RUNX2’s isoform 9. The changes in protein production with BMP4 were more prominent in WT compared to the mutants. BMP4 treatment also had a stronger effect on ALPL, as well as COL10A1 and IHH, in V620I compared to T89I. These data have been added to Figure 5 and Figure 5 —figure supplement 1, and the text has been updated.</p><disp-quote content-type="editor-comment"><p>4. It is known that RNA-seq measures a rough expression level of a transcript so RT-PCR verification is often performed. Therefore, the RT-PCR analysis of expression levels of the identified genes, ALPL, AMELX, IFITM5, and others, should be considered as an addition to Figure 6.</p></disp-quote><p>We appreciate the reviewer’s suggestion to verify the RNA-seq data with RT-qPCR. Several groups have published that RNA-seq methods are more quantitative than RT-qPCR and do not require RT-qPCR verification (Coenye, 2021; Everaert et al., 2017). Nonetheless, we compared chondrogenic gene expression at day 28 of chondrogenesis and saw similar patterns between RT-qPCR and RNA-seq. The BMP4 RNA-seq data set was further confirmed as we compared gene expression to protein expression with western blots of hypertrophy markers, including ALPL, and saw consistent results (Figure 5 – Figure S1). These data have been added to the manuscript, and we believe the RNA-seq data has been validated.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>In this manuscript, Dicks et al. generated two human iPSC lines with TRPV4 mutations (mild V620I or lethal T89I) using a CRISPR-Cas9 approach and examined their channel function and differentiation abilities into chondrocytes. While their initial goal is to elucidate the detailed molecular mechanisms underlying how these two mutations lead to strikingly distinct severities of skeletal dysplasias, most of their data found that these two mutations behave in a similar manner. The minor differences they found are: 1) increased basal currents in V620I cells; 2) reduced mechanical properties of cartilage matrix in V620I chondrocytes; 3) some differences in DEGs of RNA-seq data. They also stated that &quot;The severe T89I mutation inhibits chondrocyte hypertrophy more than moderate V620I 298 mutation&quot; (page 16). However, no substantiated data were provided to support this conclusion. While a serial of RNA-seq experiments were performed to explore the underlying mechanism, they were not followed by validation experiments to pinpoint the exact pathways or molecular mechanisms. Thus, although using CRISPR-Cas9 and iPSCs are novel and potentially important, this manuscript is overall descriptive with limited mechanistic information.</p></disp-quote><p>We thank the reviewer for the summary of the paper. We have further investigated the differences between WT and the two mutant lines to add to the RNA-seq experiments. As suggested by another reviewer, we looked at protein kinase gene expression, which may be altering TRPV4 phosphorylation and ultimately changes in channel activation. This expression data is consistent with the basal calcium differences we saw, and we believe these warrant further investigation in a follow-up study regarding biochemical changes to the channel structure and activation.</p><p>We also further validated the differences in BMP4-induced hypertrophy by looking at protein production. BMP4 not only increased hypertrophic proteins COL10A1, ALPL, IHH, and RUNX2, but we saw much larger increases in WT compared to mutants. Further, ALPL production was increased in the moderate V620I mutation compared to the severe T89I mutation, indicating a potential player in the differences in disease severity caused by the two mutants.</p><p>Finally, we investigated the DEGs between V620I and T89I to highlight the differences between the two mutations. We believe this study has served as a foundation for identifying potential mechanisms leading to the disease phenotypes of moderate and severe skeletal dysplasias. In future studies, we hope to validate these mechanisms</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>TRPV4 is an ion channel protein and mutations in TRPV4 gene resulted in different types of skeletal defects. In this study, the authors created two types of TRPV4 mutations (mild V620I and lethal T89I mutations) in human iPS cells through CRISPR-Cas9 gene editing. They found that mutations of TRPV4 accelerated calcium signaling and reduced response of calcium signaling to TRPV4 agonist. In addition, the V620I mutation led to decreased mechanical properties of cartilage matrix later in chondrogenesis. TRPV4 mutations also upregulated HOX genes and downregulated antioxidant genes, such as CAT and GSTA1, through entire chondrogenesis process. BMP4-induced chondrocyte hypertrophy was also inhibited in TRPV4 mutant cells. This study provided novel information about the functions of TRPV4 in chondrogenesis and help us understand the skeletal dysplasia observed in patients with TRPV4 mutations.</p><p>The study was well designed with novel approach and state-of-the -art technology. The experiments were well executed and information gained from this study is valuable. To further improve this manuscript, few suggestions need to be considered.</p><p>1)In this study, several chndrogenic marker genes were altered in TRPV4 mutant cells and these genes are regulated by Runx2, such as Col10a1. It is not clear if Runx2 expression is changed in TRPV4 mutant cells.</p></disp-quote><p>We thank the reviewer for their suggestion to investigate RUNX2 expression. We found that <italic>RUNX2</italic> gene expression was significantly increased with BMP4 treatment in the WT line but not in the mutant lines. Additionally, <italic>RUNX2</italic> gene expression was significantly higher in BMP4-treated WT compared to BMP4-treated mutants. We also looked at RUNX2 protein production using western blot, in addition to other hypertrophic markers. We found that not only was RUNX2 expressed in the samples, specifically so was the RUNX2 isoform 9. BMP4-treated WT had higher protein production of both RUNX2 and RUNX2-9 compared to BMP4-treated mutants. BMP4 treatment increased RUNX2-9 production more (than RUNX2) in the mutants compared to their TGFβ3 controls.</p><disp-quote content-type="editor-comment"><p>2)The authors found changes in Wnt3a, Wnt7a and Wnt7b expression in TRPV4 mutant cells. Do the authors know if β-catenin protein levels were altered in TRPV4 mutant cells.</p></disp-quote><p>We appreciate the reviewer’s suggestion to look at β catenin given the differences in <italic>WNT3A, WNT7A</italic>, and <italic>WNT7B</italic> gene expression. We looked at our RNA seq data to identify if there were differences in β-catenin. We found that expression of <italic>CTNNB1</italic> was similar between the three lines at both day 28 and day 56. However, T89I, the severe TRPV4 mutation, had significantly higher <italic>CTNNB1</italic> expression compared to WT after 56 days of chondrogenic differentiation.</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-71154-sa2-fig2-v2.tif"/></fig><p>References</p><p>Adkar, S. S., Wu, C. L., Willard, V. P., Dicks, A., Ettyreddy, A., Steward, N.,... Guilak, F. (2019). Step-Wise Chondrogenesis of Human Induced Pluripotent Stem Cells and Purification Via a Reporter Allele Generated by CRISPR-Cas9 Genome Editing. <italic>Stem Cells, 37</italic>(1), 65-76. doi:10.1002/stem.2931</p><p>Camacho, N., Krakow, D., Johnykutty, S., Katzman, P. J., Pepkowitz, S., Vriens, J.,... Cohn, D. H. (2010). Dominant TRPV4 mutations in nonlethal and lethal metatropic dysplasia. <italic>Am J Med Genet A, 152A</italic>(5), 1169-1177. doi:10.1002/ajmg.a.33392</p><p>Cao, S., Anishkin, A., Zinkevich, N. S., Nishijima, Y., Korishettar, A., Wang, Z.,... Zhang, D. X. (2018). Transient receptor potential vanilloid 4 (TRPV4) activation by arachidonic acid requires protein kinase A–mediated phosphorylation. <italic>Journal of Biological Chemistry, 293</italic>(14), 5307-5322. doi:10.1074/jbc.m117.811075</p><p>Coenye, T. (2021). Do results obtained with RNA-sequencing require independent verification? <italic>Biofilm, 3</italic>, 100043. doi:10.1016/j.bioflm.2021.100043</p><p>Dicks, A., Wu, C. L., Steward, N., Adkar, S. S., Gersbach, C. A., &amp; Guilak, F. (2020). Prospective isolation of chondroprogenitors from human iPSCs based on cell surface markers identified using a CRISPR-Cas9-generated reporter. <italic>Stem Cell Research &amp; Therapy, 11</italic>(1), 66. doi:10.1186/s13287-020-01597-8</p><p>Everaert, C., Luypaert, M., Maag, J. L. V., Cheng, Q. X., Dinger, M. E., Hellemans, J., &amp; Mestdagh, P. (2017). Benchmarking of RNA-sequencing analysis workflows using whole-transcriptome RT-qPCR expression data. <italic>Scientific Reports, 7</italic>(1). doi:10.1038/s41598-017-01617-3</p><p>Fan, H. C., Zhang, X., &amp; McNaughton, P. A. (2009). Activation of the TRPV4 ion channel is enhanced by phosphorylation. <italic>Journal of Biological Chemistry, 284</italic>(41), 27884-27891. doi:10.1074/jbc.M109.028803</p><p>Kang, S. S., Shin, S. H., Auh, C.-K., &amp; Chun, J. (2012). Human skeletal dysplasia caused by a constitutive activated transient receptor potential vanilloid 4 (TRPV4) cation channel mutation. <italic>Experimental and Molecular Medicine, 44</italic>(12), 707. doi:10.3858/emm.2012.44.12.080</p><p>Peng, H., Lewandrowski, U., Muller, B., Sickmann, A., Walz, G., &amp; Wegierski, T. (2010). Identification of a Protein Kinase C-dependent phosphorylation site involved in sensitization of TRPV4 channel. <italic>Biochem Biophys Res Commun, 391</italic>(4), 1721-1725. doi:10.1016/j.bbrc.2009.12.140</p><p>Rock, M. J., Prenen, J., Funari, V. A., Funari, T. L., Merriman, B., Nelson, S. F.,... Cohn, D. H. (2008). Gain-of-function mutations in TRPV4 cause autosomal dominant brachyolmia. <italic>Nature Genetics, 40</italic>(8), 999-1003. doi:10.1038/ng.166</p><p>Sun, S. (2012). The Mutation of Transient Receptor Potential Vanilloid 4 (TRPV4) Cation Channel in Human Diseases. In Kang (Ed.), <italic>Mutagenesis</italic>. InTech.</p><p>Wu, C. L., Dicks, A., Steward, N., Tang, R., Katz, D. B., Choi, Y. R., &amp; Guilak, F. (2021). Single cell transcriptomic analysis of human pluripotent stem cell chondrogenesis. <italic>Nat Commun, 12</italic>(1), 362. doi:10.1038/s41467-020-20598-y</p></body></sub-article></article>